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SUMMARY 
This thesis describes the development of a series of novel pyrimidine- and purine bioisosters. 
Systematically purines are called imidazo[4,5-d]pyrimidine. In nucleoside chemistry the 
synthesis and incorporation of N9-purinylnucleoside - glycosylated at the imidazole nitrogen 
atom is well established. In these cases the classical Watson-Crick base pairing A-U (T), G-C 
is observed. This study deals with the chemical synthesis of N1-glycosylated 
purinylnucleoside building blocks. In this substance-class, bearing the sugar moiety at the 
pyrimidine nitrogen, beside the classical Watson-Crick-base pairing additional hydrogen 
bridges to the unsubstituted imidazole moiety are conceivable. 
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are given in the form of the 
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The second part of this thesis deals with the development and synthesis of a novel, flexible 
purine bioisoster, which also can be described as a glycosylated dihetaryl amine derivative. In 
this novel class the typical purine and pyrimidine recognition elements are retained. 
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The proposed dihetaryl amines may either be obtained by palladium catalysed amination 
reaction or via reductive desulfurination of the 3-cyclic azaphenothiazin precursor. 
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ZUSAMMENFASSUNG 
In dieser Arbeit wird die Darstellung einer Gruppe von neuen Purin- und Pyrimidin 
Bioisosteren diskutiert.  
Der systematische Name von Purin lautet Imidazo[4,5-d]pyrimidine. Als Nucleosidbausteine 
finden vor allem die am Imidazolring glycosylierten N9-Purinylnucleoside Anwendung. Beim 
Einbau in Oligonucleotide wird die klassische Watson-Crick Basenpaarung A-U(T), G-C 
beobachtet. In dieser Studie wurden am N1 glycosylierte Purinylnucleosidbausteine 
hergestellt. In dieser am Pyrimidinstickstoff glycosylierten Verbindungsklasse sind neben der 
klassischen Watson-Crick-Basenpaarung auch weitere Wasserstoffbrückenbindungen zum 
unsubstituierten Imidazolteil des Nucleosides vorstellbar.  
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Im zweiten Teil wird die Synthese eines neuartigen, flexiblen Purinbioisosters diskutiert, das 
sich als glycosyliertes Dihetarylamin beschreiben lässt. Dabei werden die charakteristischen 
Erkennungselemente für sowohl Purine alsauch für Pyrimidine beibehalten. 
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Die Synthese des zugrunde liegenden Dihetarylamins erfolgt entweder durch eine 
palladiumkatalysierte Aminierungsreaktion oder durch reduktive Entschwefelung des  
3-cyclischen Azaphenothiazin Vorläufers 
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One never notices what has been done; one can only see what remains to be done.  
Marie Curie 
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INTRODUCTION 
Nitrogen containing heterocyclic compounds featured prominently in early studies of 
chemistry and they were closely associated with the development of “organic” chemistry, 
which was concerned with the study of materials isolated from living sources, whilst 
“inorganic” chemistry dealt with the study of inanimate materials.  
Over the years, the pyrimidine1 and purine2 systems turned out to be important 
pharmacophors, interacting with the synthesis and function of nucleic acids.  
When one inspects the relevant literature, one recognizes that, during recent years, purine 
chemistry has enjoyed a renaissance. Purine receptors -particularly adenosine receptors3 - are 
found in all organs of the human body, and the aim of modern purine research is to find new 
agonists and antagonists for purine receptors.4  
Four adenosine receptor sub-types, A1, A2A, A2B, and A3, which have been all cloned, are 
currently known. Purine derivatives, needed as tools to study these receptors, also have the 
potential to be pharmacologically active. Thus, adenosine receptors play an important role in 
blood pressure regulation (besides adrenaline and angiotensine receptors).  
Moreover: i) These receptors are important for the regulation of pain signals, e.g., when  
A1-receptors are activated, pain signal transmission is inhibited, leading to local analgesia. ii) 
In certain tumour tissues, A3 receptors are over expressed, and application of A3 agonists 
inhibits the growth of cancerous cells. iii) In the ongoing battle against asthma, new A2A 
agonists are looked upon as alternatives for glucocorticoides. 
In this chapter the synthesis of a series of new pyrimidine- and purine bioisosters is described. 
A series of novel N1-purinyl nucleosides has been investigated as possible pyrimidine 
bioisosters, whereas split-nucleosides, likewise bearing imidazole- and pyrimidine rings, have 
been developed as novel purine bioisosters. 
According to the definition of Hansch, structures are called bioisoster when showing the same 
biological activity. 5 The investigation wheter these new compounds fulfil the biological 
requests of being a bioisoster is currently under process.  
                                                 
1) Lagoja, I., Chemistry & Biodiversity, 2005, 2, 1-50. 
2) Rosemeyer, H., Chemistry & Biodiversity, 2004, 1, 361-401. 
3) Van der Wenden E.M., von Frejtag, D., Künzel, J.K., Mathot, R.A.A., Danhof, M.,. Iizerman, A.P, Soudijn, 
W., J. Med. Chem., 1995, 38, 4000. 
4) Camaioni, E., Costanzi, S., Vitori, S., Volpini, R., Klotz, K.-N., Cristalli, G., Bioorg. Med. Chem. Lett. 
1998, 6, 523; http://www.nottingham.ac.uk/~mqzwww/adenosine.html. 
5) Hansch, C., Intra-Science Chem. Rep., 1974, 8, 17. 
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1. N
1
-PURINYLNUCLEOSIDES 
Nucleosides were among the first organic compounds formed at beginning of evolution in the 
early history of our planet earth. It is still believed that these nucleosides have been formed by 
reaction of a heterocycle with sugars. To support this hypothesis, guanine and adenine were 
heated with D-ribose in sea water, containing the Lewis acid magnesium chloride as catalyst6 
obtaining guanosine and adenosine, whereas the in vitro synthesis of pyrimidine nucleosides 
remains as yet an enigma. 
The introduction of Friedel-Crafts catalysts such as SnCl4
7 in 1970-1976 for the sugar-base 
condensation reaction as a more effective version of the Silyl-Hilbert-Johnson synthesis of 
nucleosides, was followed in 1975 by the use of the Lewis acid trimethylsilyl triflate 
TMSOTf in the condensation reaction.8 The whole range of the different methods for 
pyrimidine and purine nucleoside syntheses as well as the syntheses of nucleosides of various 
heterocycles has been excessively reviewed previously.9 
It turned out that TMSOTf, a much weaker Lewis acid than SnCl4, is a superior, if not the 
optimal, catalyst for nucleoside synthesis. – Not only for mechanistic reasons, but also for 
simplifying the work-up procedure. By addition of an ice-cold solution of aqueous sodium 
bicarbonate to the reaction mixtures no emulsions are obtained as nearly always encountered 
on aqueous workup of reactions employing SnCl4. Ethylene chloride (which favors σ-complex 
formation of the purine moieties with TMSOTf and which also favors the rearrangement of 
the initially formed kinetically controlled intermediates to give eventually the 
thermodynamically most stable products) is thus the preferred solvent for the synthesis of 
purine nucleosides.222, 223 Understanding the mechanisms involved in these reactions is 
essential for their effective application. One of the aims of this project was the isolation and 
characterization of the kinetically controlled products and to incorporate the obtained purinyl-
                                                 
6) a) Fuller, W.D., Sanchez, R.A., Orgel, L.E., J. Mol. Evol., 1972, 1(3), 249-57; b) Fuller, W.D., Sanchez, 
R.A., Orgel, L.E., J. Mol. Biol., 1972, 67(1), 25-33. 
7) a) Niedballa, U., Vorbruggen H., Angew.Chem. (Int. ed.), 1970, 9(6), 461-2. b) Niedballa, U., 
Vorbrueggen, H., J. Org. Chem., 1974, 39(25), 3654-9; c) Niedballa, U., Vorbrueggen, H., J. Org. Chem. 
1974, 39(25), 3660-63; c) Niedballa, U., Vorbrueggen, H., J. Org. Chem., 1974, 39(25), 3664-7; d) 
Niedballa, U., Vorbrueggen, H., J. Org. Chem., 1974, 39(25), 3668-71; e) Niedballa, U., Vorbrueggen, 
H., J. Org. Chem., 1974, 39(25), 3672-3; f) Niedballa, U., Vorbrueggen, H., J. Org. Chem., 1976, 41(12), 
2084-6; g) Vorbrueggen, H.; Hoefle, G. Chem. Ber. 1981, 114(4), 1256-68. 
8) a) Vorbrueggen, H., Krolikiewicz, K., Angew. Chem., 1975, 87(11), 417; b) Vorbrueggen, H., 
Krolikiewicz, K., Bennua, B., Chem. Ber., 1981, 114(4), 1234-55. 
9) a) Vorbruggen, H., Ruh-Pohlenz, C. “Synthesis of nucleosides” Organic Reactions (New York) 2000, 55, 
1-630. b) Vorbrueggen, H., Ruh-Pohlenz, C. “Handbook of nucleoside synthesis” Wiley Interscience, 
New York, 2001; 
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nucleosides into oligonucleotides as a novel group of pyrimidine bio-isosters, offering an 
additional possibility of Hoogsteen pairing, due to the present imidazole moiety. The reaction 
mechaninsm of the Vorbrüggen condensation was investigated with adenine and 
hypoxanthine to obtain pyrimidine bioisosters bearing a hydrogen-bridge donor (adenine) as 
well as an acceptor (hypoxanthine). Furthermore, the obtained nucleosides should be 
evaluated for their activity against DNA viruses, RNA viruses and against HIV-1 and HIV-2. 
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Scheme 1. Lewis acid catalysed glycosylation of N6-Bz-adenine  
On the basis of 13C-NMR-studies7g (following the downfield shift of C8) it is assumed that the 
most basic N1-nitrogen in persilylated N6-benzoyl-adenine 3 is trimethylsilylated by TMSOTf 
2 to form the σ-complex 4. This complex eliminates 2 to form the activated putative isomeric 
silylated N6-benzoyl-adenine 5. Vorbrüggen and Ruh-Pohlenz9 have suggested that 
compounds 3, 4 or 5 react reversibly with the sugar salts 1 in an initially kinetically controlled 
reaction to give the protected N1-nucleoside 6 and the N3-adenosine 7. The latter can be 
Results and Discussion 
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isolated at the start of the reaction but 6 and 7 occur in equilibrium with 5 and 1 (Scheme C1). 
Subsequent reaction of 5 with the sugar salt 1 furnishes primarily a mixture of the undesired 
protected N7-nucleoside 8 and the desired N9-nucleoside 9. On boiling the reaction mixture in 
the rather unpolar solvent ethylene chloride (compared to acetonitrile) σ-complex formation 
of the undesired products 6, 7 and 8 with TMSOTf 2 is favored and thus rearrangement and 
formation of equilibria between 6, 7 and 8 with 5 and the sugar salts 1 occurs (cf. the depicted 
TMSOTf 2 catalyzed cleavage of 8 to 5 and 1). This eventually results in the nearly exclusive 
formation of the desired and thermodynamically favored protected natural N9-nucleoside 
adenosine 9. On saponification of 9 with methanolic ammonia, crystalline adenosine is 
obtained in 81% overall yield starting from 2 and 3.8b 
However, it can be demonstrated, that on reacting N6-isobuturyl-adenine 10 in the presence of 
TMSOTf 2 with 1,2,3,5-tetra-O-acetyl-ß-D-ribofuranose 11 (whose bridged cation 
corresponding to 1 is less stable than that of the benzoylated intermediate 1 and whose 
nucleosides consequently rearrange more slowly) the initially formed N1-nucleoside 6 can be 
isolated, together with the corresponding N9-nucleoside 9 as well as the N1,N9-bisriboside 12, 
as the major product (Scheme C2).  
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Scheme 2. Synthesis of N1-ribofuranosyladenine 13 
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These results also were confirmed from Boryski et. al.10 To stabilize the initially formed 
kinetic products the reaction is carried out in acetonitrile under exclusion of oxygen. 
Saponification with methanol /ammonia results in crystalline N1-ribofuranosyladenine 13. 
Table C1. Comparison of 1H and 13C NMR shifts of N9- and N1-adenosine  
 N
9
-adenosine N
1
-adenosine 
1
H-NMR H1´ 5.91 d, J = 6.2 Hz H1´ 5.95 d, J=6.0 Hz 
sugar H2´ 4.64 m H2´ 4.12 t, J=5.4 Hz 
 H3´ 4.17 m H3´ 4.12 d 
 H4´ 3.99 m H4´ 4.07 d 
 H5´ 3.68 m, 2H H5´ 3.72 m, 2H 
 2-, 3-, 5-OH 5.20, 5.49 m, br, ex 3H 2-, 3-, 5-OH 3.38 br, s, ex, 3H 
1
H-NMR H-2 8.37 s H-2 8.39 s 
base H-8 8.16 s H-8 7.83 s 
 NH2 7.38 br, s, ex NH2 6.80 br, s, ex 
13
C-NMR C1´ 88.4 C1´ 92.23 
sugar C2´ 73.9 C2´ 72.74 
 C3´ 71.2 C3´ 69.90 
 C4´ 86.4 C4´ 86.27 
 C5´ 62.2 C5´ 60.55 
13
C-NMR CH-2 152.9 CH-2 140.54 
base C-4 149.5 C-4 154.70 
 C-5 119.8 C-5 118.99 
 C-6 156.6 C-6 148.68 
 CH-8 140.5 CH-8 150.73 
 
In order to obtain building blocks suitable for 
oligonucleotide synthesis protection of N9 and N6 
and 5´-OH were investigated. However, all 
attempts of benzoyl protection of the amino 
functions as well as the introduction of a mono-
methoxytrityl protection of the 5´-OH failed. In 
the X-ray structure11 of N1-adenosine it can be 
seen that the tautomer of 1-ribofuranosyl-1H-
purine-6-amine 13 is found in place of 1-
                                                 
10) Boryski, J., Framski, G. Coll. Sympos. Series 2005, 7 (Chemistry of Nucleic Acid Components), 177-181. 
11) X-ray structure was kindly provided from Prof. Jerzy Boryski, Poznan University, Poland. 
Figure 1. X-ray structure of N1 adenosine 13 
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ribofuranosyl-1,9-dihydro-6H-purin-6-imine 13a. This may explain the difficulties to protect 
the position N9, whereas strong hydrogen-bridge between 5´OH and the 6-NH2 causes the low 
reactivtity of these two positions. Compound 13 turned out to be stable in alkaline or neutral 
reaction conditions; however, in presence of Lewis acids a migration of the sugar moiety to 
obtain the thermodynamically more stable N9 nucleoside has been observed. 
N
1-inosine 14 also could be isolated as the kinetic product (24 % yield) obtained by 
Vorbrüggen-Condensation of hypoxanthine and 1,2,3,5-tetra-O-acetyl-ß-D-ribofuranose 11. 
However, a more favorable approach starts from 6-chloropurine 15. After protection of  
9-position to obtain 16, the 6-chloro can be converted to a hydroxy function by refluxing in 
1N NaOH yielding 17. Glycosylation to 18 followed by selective deprotection to 19 finally 
afforded N1-inosine 14 (Scheme 3).  
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Scheme 3. Synthesis of N1-inosine 14 
In first instance a benzyl protecting group has been applied, however, reductive deprotection 
was difficult at best. Also allyl-protection was not favourable since the conversion to the  
9- protected hypoxanthine derivative 17 suffered from bad yield. These difficulties could be 
overcome using a 4-methoxybenzyl protecting group, which could be smoothly removed 
under mild oxidative conditions (NH4)2Ce(NO3)3. Saponification with MeOH / NH3 finally 
derives N1-inosine 14 in good yield. 
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Table 2. Comparison of 1H NMR shifts of N9- and N1-inosine  
 N
9
-inosine N
1
-inosine 
1
H-NMR H1´ 5.88 d, J = 5.73 Hz) H1´ 6.15 d, J = 4.12 Hz 
sugar H2´ 4.49 m H2´ 4.00 m. 3H 
 H3´ 4.12 m H3´ 4.00 m. 3H 
 H4´ 4.00 m H4´ 4.00 m. 3H 
 H5´ 3.55-3.60 m, 2H H5´ 3.68 m, 2H 
 2-, 3-, 5-OH 5.06, 5.18, 5.48 m, br, ex 2-, 3-, 5-OH 5.50 m, br, ex 
1
H-NMR H-2 8.07 s H-2 8.55 s 
base H-8 8.34 s H-8 8.09 s 
 NH / OH 12.38 s, br, ex NH / OH 5.50 br, m, ex 
As a last product of the series of N1-nucleosides, N1-xanthosine 20 has been prepared by total 
synthesis starting from 6-aminouracil 21. Vorbrüggen Condensation exclusively derives the 
N
3 glycosylated derivative 22. The formation of the N3 isomer 22 was verified by NOE-
Difference Spectroscopy (i.e. irradiation of the (1)NH causes a 12 % NOE at the exocyclic 
amino group). A nitrosation / reduction sequence proved not applicable due to decomposition 
problems of the nitroso intermediate.  
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Scheme 4. Synthesis of N1-xanthosine 20 
However, the problem could be circumvented by preparing the diazo-intermediate 23 
followed by reductive cleavage (H2 / Pd-C) to obtain the 5,6-diaminopyrimidyl derivative 24. 
Ring closure with diethoxyethyl acetate affords the protected xanthosine 25 in moderate yield. 
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Finally, upon saponification with MeOH / NH3 the desired N
1-xanthosine 20 is obtained 
(Scheme 4). 
Table 3. Comparison of 1H NMR shifts of N9- and N1-xanthosine  
 N
9
-xanthosine N
1
-xanthosine 
1
H-NMR H1´ 5.73 d, J = 6.84 Hz H1´ 6.04 (d, J = 1.8 Hz), 
sugar H2´ 4.22 m H2´ 4.42 m 
 H3´ 4.06 m H3´ 3.54 m 
 H4´ 4.01 m H4´ 3.54 m 
 H5´ 3.66 m, 2H H5´ 3.54 m 
 2-, 3-, 5-OH 5.28, 5.48 m, br, ex 2-, 3-, 5-OH 5.00 m, br, ex 
1
H-NMR H-2 7.87 s H-2 8.04 s 
base NH / OH 10.87 NH / OH 6.37, 8.60, br, ex 
The nucleosides 13, 14 and 20 have been evaluated for their activity against DNA viruses, 
RNA viruses and against HIV-1 and HIV-2. However, no significant activity or toxicity has 
been found.  
2. SPLIT-NUCLEOSIDES 
Purines are the most widely distributed heterocycles in nature. They appear in nucleic acids, 
are part of the energy supply mechanism (ATP) of the cell, they may function as cofactor 
(NAD) and ligands for receptors. In all these cases, the purine base is involved in molecular 
recognition and a perfect fit between ligand and protein is important for biological activity. 
All purinergic targets (ATP, NAD, receptors, nucleic acids) have been exploited for 
antagonist design (i.e. for the development of new potential drugs).  
Therefore it might be important to develop a new general concept for modifying purine bases 
that can be used in the drug discovery process. The aim of this project is the search for a 
boycotter of purine bases and the use of this concept in several fields of inhibitor design.  
One way to realize this concept is to develop “split” purine nucleosides in order to retain the 
typical purine recognition elements (i.e. the pyrimidine and the imidazole moiety) and to 
increase flexibility of the ring system to increase the adaptability to biological targets.  
Results and Discussion 
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Figure 2. General structure of split-nucleosides 
This concept has been developed before mostly for the sugar moiety (i.e. acyclic nucleosides) 
of nucleosides but it is unexplored for the base moiety. 
The flexibility of a base is of utmost importance for the biological function of a nucleoside. In 
naturally occurring nucleotides the anti conformation (as shown in Figure C2) predominates, 
however, examples of the syn conformation are known. For example, the conformation of the 
base at the glycosidic bond shows a high impact on the enzymatic reactions catalyzed by  
5'-nucleotidase and adenosine deaminase.12 The importance of purine recognition in 
biomedical research can be demonstrated with several examples.  
As an example at the level of receptors, adenosine has an important role in modulating the 
function of the cardiovascular, endocrine, and nervous system.13 Till now, four receptor sub-
types (A1, A2A, A2B, and A3)14 are known and have been all cloned and pharmacologically 
characterized. Purines are needed as tools for the study of these receptors, and purine 
analogues have the potential to function as new pharmacologically active compounds.15 Untill 
now, nucleoside ligands at the agonist-antagonist boundary have been either modified at the 
sugar,16 or the intact purine moiety has been manipulated by substitution.17 Due to their 
flexible character and specific recognition abilities the here proposed split-nucleosides 
represent a new generation of potential purine receptor agonists and antagonists. With the 
                                                 
12)  Stolarski, R., Dudycz, L., Shugar, D., Eur. J. Biochem., 1980, 108, 111-121. 
13)  Daly, J.W., J. Med.Chem., 1982, 25, 197. 
14)  Olah, M.E., Stiles, G.L., Pharmacol.Ther., 2000, 85, 55-75. 
15)  a) Jacobson, K.A., Knutsen, L.S., in “Purinergic and Pyrimidinergic Signaling I”, Handbook of 
Experimental Pharmacology, Vol. 151/I, Abbracchio, M.P, Williams, M, Eds., Springer-Verlag: Berlin, 
Germany, 2001, 129 – 175; b) Müller, C.E., Curr. Med. Chem., 2000, 7, 1269 – 1288. 
16)  Gao, Z.G., Kim, S.K., Biadatti, T., Chen, W., Lee, K., Barak, D., Kim, S.G., Johnson, C.R., Jacobson, 
K.A. J. Med. Chem., 2002, 45, 4471 – 4484. 
17) a) Beauglehole, A.R., Baker, S.P., Scammells, P.J., Biorganic & Med.Chem. Let., 2002, 12, 3179-3182; 
b) Rieger, J.M., Brown, M.L., Sullivan, G.W., Linden, J., Macdonald, T.L., J. Med. Chem., 2001, 44, 
531-539. 
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increasing availability of crystal structures for various enzyme-substrate complexes, it has 
become apparent that many binding sites for purine nucleosides are more flexible than 
previously assumed and can, therefore, adjust to fit to a wide range of substrates.18 The split-
nucleosides still have the molecular elements needed for recognition and they provide a 
unique perspective to investigate enzyme binding-site parameters. This information might 
serve to overcome the problems typically associated with using crystallographic data in 
modelling when dealing with flexible enzyme binding sites. The obtained data may be used to 
design a second-generation of more effective inhibitors. An example of this approach is the 
search for inhibitors of S-adenosyl-L-homocysteine hydrolase19 (an antiviral target) which 
may evaluate the concept at the level of enzyme recognition.  
At the level of DNA recognition, the flexibility and the possible variation of the substitution 
pattern of both heterocyclic rings of the split-nucleosides allows specific purine and / or 
pyrimidine recognition by the same molecule. This makes them unique candidates for 
investigation of hybridization properties within the double- and triple-helix motif and for 
nucleic acid-protein interactions. The degeneracy of the genetic code leads to a multitude of 
possible DNA sequences coding for a particular protein. Oligonucleotides taking this 
redundancy into account must be synthesized and used for the screening of the potential DNA 
or RNA candidates. This has led to the concept of mixed primers or probes. The fundamental 
problem of this approach is reflected by the fact that the replacement of natural nucleosides by 
a chemically modified congener within a certain sequence may have an impact on the helix-
form (A, B, Z).20 The use of less discriminatory base analogs (universal or ambiguous bases21) 
has not fulfilled the expectations yet, despite of twenty years of research. A true universal 
base should hybridize with all four natural bases without discrimination and significant 
destabilization of the DNA duplex. The split-nucleosides, as proposed here, increases the 
potentiality for discovery of new universal base moieties. Besides the antisense gene therapy, 
which aims to turn off a mutated gene in a cell by targeting the mRNA transcripts copied from 
the gene, triple-helix-forming oligonucleotide gene therapy targets the DNA sequence of a 
                                                 
18) a) Hu, Y., Yang, X., Yin, D., Mahadevvan, J., Kuczera, K., Schowen, R.L., Borchardt, R.T., Biochem., 
2001, 40, 15143; b) Yin, D., Yang, X., Hu, Y., Kuczera, K., Schowen, R.L., Borchardt, R.T. Squier, T.C., 
Biochem., 2000, 39, 8323. 
19) Seley, K.L., Quirk, S., Salim, S., Zhang, L., Hagos, A., Biorg. & Med. Chem. Let., 2003, 13, 1985 - 1988 
20)  Luyten, I., Herdewijn, P., Eur. J. Med. Chem., 1998, 33, 515-576. 
21)  a) Loakes, D., Brown, D.M., Linde, S., Hill, F., Nucleic Acids Res., 1995, 23, 2361–2366; b) Loakes, D., 
Brown, D.M., Nucleic Acids Res., 1994, 22, 4039–4043; c) Nichols, R., Andrews, P.C., Zhang, P., 
Bergstrom, D.E., Nature, 1994, 369, 492–493; d) Moran, S., Ren, R.X.-F., Kool, E.T., Proc. Natl Acad. 
Sci. USA, 1997, 94, 10506–10511; e) Takeshita, M., Chang, C.-N., Johnson, F., Will, S., Grollman, A.P. 
J. Biol. Chem., 1987, 262, 10171–10179. 
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mutated gene to prevent its transcription. This technique involves the delivery of short, single-
stranded oligonucleotides (TFO), binding specifically in the groove between the double 
strands of the mutated gene's DNA.22 This produces a triple-helix structure preventing that 
segment of DNA from being transcribed into mRNA.23 Reverse Transcription of retroviral 
RNA into double-stranded DNA is catalyzed by the reverse transcriptase (RT). A highly 
conserved polypurine tract, PPT, which is found twice, in HIV-1 viral RNA and in the nef 
gene adjacent to U3 and in the pol gene, serves as primer for plus strand DNA synthesis. The 
PPT and seven additional purine nucleotides24 constitute a suitable target for triple-helix 
formation inhibiting the RT and RNaseH activities. Therefore, the incorporation of the 
flexible split-nucleosides into oligonucleotides allows the investigation of a new generation of 
TFOs. 
2.1. Synthesis of Di-Hetaryl Amines by Hartwig-Buchwald Condensation 
(Method A): 
Di-hetaryl amines can be prepared by direct condensation of a hetarylamine with a hetaryl-
halogen compound. Condensation can be achieved in acidic25 – or alkaline26 medium, 
however, yields are not satisfying. In heterocyclic chemistry, the formation of a new  
C-N bond using palladium catalyzed amination reaction has received growing attention.27 A 
possible catalytic cycle is given in Scheme 5.  
At first instance, a Pd-BINAP (2,2´-bis(dipenylphosphino)-1,1´-binaphtyl) complex is formed 
which can undergo oxidative addition of the hetarylhalogen compound. Further coordination 
of the amine affords an amido complex, which in turn can undergo reductive elimination to 
form the desired product and regenerating the Pd(0) catalyst. 
                                                 
22)  Szewczak, A.A., Ortoleva-Donnelly, L., Ryder, S.P., Moncoeur, E., Strobel, S.A. Nature Struct. Biol., 
1998, 5 (12), 1037 – 1042. 
23) Vuyisich,M, Beal, P.A., Nucl. Acids Res. 2000, 28 (12), 2369 – 2374. 
24)  a) Volkmann, S., Jendis J., Frauendorf, A., Moelling, K., Nucleic Acid Res., 1995, 23, 1204-1212; b) 
Jendis, J., Strack, B., Volkmann, S., Moelling, K., AIDS Res Hum Retroviruses, 1996, 12, 1161-1168. 
25)  Banks, K., J. Am. Chem. Soc., 1944, 1131. 
26) Banks, K., J. Am. Chem. Soc., 1944, 1127-1130. 
27) for review see: a) Wolfe, J.P., Wagaw, S., Marcoux, J.F., Buchwald, S.L., Acc. Chem. Res., 1998, 31, 
805– 818; b) Hartwig, J.F., Angew. Chem. Int. Ed. 1998, 37, 2046– 2067; further references: c) Driver, 
M.S., Hartwig, J.F. J., Am. Chem. Soc., 1996, 118, 7217 – 7218; d) Stauffer, S.R., Lee S., Stambuli, J.P., 
Hauck, S.I., Hartwig, J.F., Org. Lett., 2000, 2, 1423; e) Wolfe, J.P., Buchwald, S.L., Angew. Chem. Int. 
Ed., 1999, 38, 2413- 2416; f) Wolfe, J.P., Buchwald, S.L., J. Org. Chem. 2000, 65, 1144-1157; g) Ali, 
M.H., Buchwald, S.L., J. Org. Chem. 2001, 66, 2560 - 2565. 
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Scheme 5. Catalytic cycle of Pd-catalysed amination reaction 
The solubility of amines HN(R)H 26 in xylene or dioxane limits the use of this methology. 
However, using the above method allows the condensation of anilines 26a, aminopyridines 
26b and aminopyrimidines 26c with i.e. 4-6-dichloropyrimidine 27 (Scheme 6). 
N N
Cl ClY
X
NH2
+ 
X
Y
N N
N
Cl
H
Pd(Ac)2
+ BINAP
KOtBu
dioxane (dry)
or xylene (dry
80°C
-
X       Y
CH      CH
CH      N
N         N
60-84 %
N
N N
N
N
H
H N
28
10 %
26 27
29
 
Scheme 6. Synthesis of di-hetaryl amines 28 (bearing two 6-membered rings) by Pd-catalyzed coupling 
Besides the desired dihetarylamine derivatives 28 in some case (i.e. using 26b as starting  
material) the bisamination product 29 could also be isolated as a minor product. Upon using 
imidazole derivatives 30 and 31, respectively, a di-hetaryl amine 32 bearing as well a  
5- as a 6-membered ring is obtained, respectivley showing even closer relationship to the 
naturally occurring purines (Scheme 7).  
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Scheme 7. Synthesis of di-hetaryl amines 32 (bearing a 5- and 6-membered ring) by Pd-catalyzed coupling 
Further modifications could be achieved by nucleophilic substitution of the chlorine to a 
hydroxyl function or methoxyfunction or by reductive removal of the chlorine using Raney 
nickel (Scheme 8).  
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Scheme 8. Further modification of the di-hetaryl amines 28  
However, should a second amino-function in position 2 of the pyrimidine ring be desired, the 
here described method28 did not work satisfyingly, and an alternative approach (compare 
Chapter 2.2) was chosen. Aniline 26a and 3-aminopyridine 26b are commercially available, 
whereas amino-imidazole derivatives 30, 31 and amino-pyrimidine derivative 26c have to be 
synthesized. 1-N-Aminoimidazole 31 can be prepared by electrophilic amination of imidazole 
                                                 
28) Prim, D., Campagne, J.-M., Joseph, D., Andrioletti, B., Tetrahedron, 2002, 58, 2041-2975. 
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using TSH 3829 (O-tosyl hydroxylamine, in situ prepared  
from ethyl-O-tosyl hydroxyimidoacetate 37) as amination reagent (Scheme 9).  
1-N-Aminoimidazole can be isolated after column chromatography in 64 % yield. 
N NH
N N
NH2
N
O TsEtO
Me
H2N
O Ts
HClO4
dry dioxane
+  TsOH
3137 38  
Scheme 9. Amination of imidazole with TSH 
Choice of the protecting group is critical, since the literature indicated that deprotection of the 
imidazole nitrogen proved to be difficult at best. Starting from 4(5)-nitroimidazole 39 reaction 
with allyl chloride allows the introduction of a protecting group at N1, which later on can be 
easily removed with KMnO4 / acetone.
30 However, reduction of the obtained 1-allyl-4-nitro-
imidazole using 10 % Pd-C (1 mol%) in dry dioxane leads to 4-amino-1-propylimidazole. To 
overcome this difficulty, POM (pivaloyloxymethyl) turned out to be the protecting group of 
choice. Product 41 is not stable in oxygen atmosphere and has to be stored under argon 
atmosphere (Scheme 10). 
N NH
O2N
N N
O2N
POM
N N
H2N
POM
H2 Pd-C
dioxane
POM-Cl
39 40 41  
Scheme 10. Synthesis of 1-POM-4-amino-imidazole 41 
4(5)-Iodoimidazole 43 was prepared from imidazole following a literature protocol.31 
Treatment of 42 with NaHSO3 allows the selective removal of two iodine functions. The 
obtained 4(5)-iodoimidazole 43 can be protected to 44 using a 4-methoxybenzyl protecting 
group (Scheme C11), which can be cleaved easily under mild oxidative circumstances. 
                                                 
29) a) Glover, E.E., Rowbottom, K.T., J., Chem. Soc. Perkin Trans. I, 1976, 376; b) Messmer, A. Hajós, G., 
J. Org. Chem., 1981, 46, 843-846.  
30) a) Lemaire-Audoire, S., Savignac, M., Genêt, J.P., Bernard, J.-M., Tetrahedron Lett., 1995, 36, 1267-
1270, b) Kimbonguila, A.M., Boucida, S., Guibe, F., Loffet, A., Tetrahedron, 1997, 53, 12525-12538; c) 
Seley, K.L., Januszczyk, P., Hagos, A., Zhang, L., J. Med. Chem., 2000, 43, 4877-4883.  
31) Panosyan, F.B., Still I.W.J., Can. J. Chem., 2001, 1110-1114. 
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Scheme 11. Synthesis of 4(5)-iodo imidazole 43 and 1-(4-methoxybenzyl)-5-iodo imidazole 44 
Due to the high cost of 4-aminopyrimidine 4832 it was prepared starting from 2-mercapto 
uracil 45. Removal of the thione function with Raney nickel affords 4-(3H)pyrimidone 46, 
which in turn can be converted into 4-chloropyrimidine 47 by reaction with POCl3-DMA 
(dimethylaniline). Nucleophilic exchange of the chlorine to an amino function is achieved 
treating 4-chloropyrimidine 47 with NH3 in dioxane (NH3 / water or NH3 / MeOH should be 
avoided, since a mixture of 4-amino- and 4-hydroxy- or 4-methoxy pyrimidine, respectively, 
is obtained) (Scheme 12).  
HN NH
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O
N NH
O
N N
Cl
N N
NH2RaNi
MeOH
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NH3 
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45 46 47 48
 
Scheme 12. Synthesis of 4-aminopyrimidine 48 
4,6-Dichloropyrimidine 50 can be obtained by treating 4,6-dihydroxypyrimidine 49 with 
POCl3 and DMA (dimethylaniline).
33 For all chlorination reactions the relationship between 
pyrimidine (1 eq.), POCl3 (11 eq.) and DMA (0.3 eq.) as well as reaction time and 
temperature during the work-up procedure play critical roles. If less DMA is used, the 
reaction time increases, a larger excess leads to problems during the work-up-procedure 
(Scheme 13).  
N N
HO OH
N N
Cl ClPOCl3
DMA
49 50  
Scheme 13. Synthesis of 4,6-dichloropyrimidine 50 
                                                 
32) a) Buschauer, A., Pharmazeutische Zeitung, 1985, 130 (33) 2067-70; b) von Angerer, S., Product class 
12: pyrimidines, Science of Synthesis, 2004, 16, 379-572. 
33) Hull, R., J. Chem. Soc., 1951, 2214. 
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2.2. Synthesis of Di-Hetaryl Amines by “splitting” Azaphenothiazine Derivatives 
(Method B) 
Till present, only a few aza-derivatives of phenothiazines have been described in literature.34 
Applying the known chemistry of phenothiazines to the aniline, pyridine, pyrimidine and 
imidazole precursors, a series of novel di-, tri- and tetraazaphenothiazines 55 and 56, 
respectively, are generated. Due to their structural relationship with known pharmacophors - 
e.g. the lin-benzadenine system35 and the phenothiazine skeleton36 - these new tricyclic 
ringsystems are tested for their fluorescent properties37 and biological activity.  
Especially their abilities as minor groove intercalators will be investigated since 
phenothiazine derivatives are known to be redox active (low reduction potential). They could 
be of potential use as probes for electrochemically-based hybridization assays and for  
DNA-mediated charge-transfer studies.38 While having intercalating properties, these 
tetraazaphenothiazine derivatives have the advantage of engaging in additional hydrogen-
bonds between the intercalator and the cavity. In addition, analogues bearing a peptide side 
chain at the nitrogen of the middle ring therefore will be investigated for their ability of 
targeting conserved regions and structures in the viral genome (interaction of Tat protein with 
the transactivation responsive sequence (TAR RNA)39).  
The acid catalyzed cyclization to azaphenothiazines 55 and 56, is considered to proceed via 
initial protonation of a pyrimidine ring nitrogen of the halogen substituted ring of 53. This 
activates nucleophilic attack by the non-protonated amino-pyrimidine function of 51. The 
resulting dihetarylamine 54, eliminates HX and forms the cyclization product  
(Scheme 14). If only a short reaction time is chosen, instead of the desired tri-cyclic 
compound the di-hetarylamine intermediate 54 could be isolated (no fluorescence at 364 nm, 
characteristic chemical shift of the bridging NH at δ = 6.89-7.54, comparable to the chemical 
shift of the NH of diphenylamine). 
                                                 
34) a) Phillips, A.P., Metha, N.B., Strelitz, J. Z., J. Org. Chem., 1962, 28, 1488 – 1490; b) Okafor, C.O., J. 
Org. Chem. 1967, 32, 2006 – 2007; c) Okafor, C.O., J. Org. Chem., 1973, 38, 4386 – 4390; d) Okoro, 
U.C., Indian J. Chem. Sec. 1990, 29B, 117 – 120. 
35) a) Leonard, N.J., Morrice, A.G., Specker, M.A., J. Org. Chem., 1975, 40, 356-366; b) Leonard, N.J., 
Kazmierczak, F., Rykowski, A., J. Org. Chem., 1987, 52, 2933 – 2935. 
36) a) Massie, S.P., Chem. Rev., 1954, 54, 797; b) Bodea, C., Silberg, I. in „Advances in Heterocyclic 
Chemistry“ ed. Katritzky, A.R., Boulton A.J., Academic Press, New York, 1968, 321 – 460. 
37) Rosendahl, M.S., Omann, G.M., Leonard, N.J., Proc. Natl. Acad. Sci. USA, 1982, 79, 3480 – 3484. 
38) Hashmi, S.A., Hu, X., Immoos, C.E., Lee, S.J., Grinstaff, M.W., Org. Lett., 2002, 4 (26), 4571 – 4574. 
39) Gait, M., Karn, J., Trends Biochem. Sci., 1993, 18, 255 – 259. 
Results and Discussion 
21 
A search for optimal conditions indicated that maximum yields could be obtained using  
0.2-1 N mineral acids (HCl, H2SO4), whereas weak acids such as acetic acid, are ineffective. 
To improve the solubility of the ortho-dihalo-compound the condensation was carried out in 
mixtures of dioxane-water (1 : 3; 1 : 4). 
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Scheme 14. Ring-Closure to azaphenothiazine derivatives in acidic medium 
The structure of the tricyclic compounds has been determined by means of HMBC and 
HMQC spectroscopy. The result is shown in Figure 3.  
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Figure 3. Results ghmbc spectra 
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Alternatively, the ring-closure reaction to obtain 55 and 56 can be carried out in alkaline 
medium (Scheme 15).40 Under these circumstances the mercapto-group turns out to  
be the stronger nucleophile, giving rise to the formation of a di-hetarylsulfide 57.  
Under the applied reaction conditions a “Smiles rearrangement”41 is taking place, again 
leading to a di-hetararyl amine 54, which can undergo ring-closure to an azaphenothiazine 
derivative 55.  
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Scheme 15. Ring-closure to azaphenothiazine derivatives in alkaline medium 
The products obtained under acidic or alkaline conditions have been proven identical by 
spectroscopic investigations.  
Characteristic for azaphenothiazine derivatives 55 and 56 is a strong 
absorption band in the ultraviolet spectrum at λ ~ 258 nm and a 
chemical shift of the thiazine NH at δ ~ 9.6 ppm. All derivatives are 
brightly colored (yellow-orange) and show melting points above 
300°C. Figure 4 shows a solution of an azaphenothiazine derivative 
in a küvette at 364 nm. 
For the here described condensation reaction two sorts of starting 
compounds, both not commercially available, are required. Direct 
bromination reaction introduces bromine into position 5 of the pyrimidine moiety. Therefore, 
                                                 
40) Okafor, C.O, Uche, I.O., Akpanisi, L.E.S., J. Het. Chem., 1981, 18, 1589-1593. 
41)  Evans, W.J., Smiles, S., J. Chem. Soc., 1935, 181. 
Figure 4: Fluorescence of 
azaphenothiazines at 364 nm 
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ortho dihalo substituted pyrimidine derivatives 53 either can be obtained by treating the 
corresponding halo-pyrimidone derivative 58 with POCl3 as exemplified by the synthesis of 
5-bromo-4-chloropyrimidine 53a (Scheme 16). In this case 4(3H)-pyrimidone 46 first is 
brominated to obtain 5-bromo-4(3H)pyrimidone 58 42 followed by chlorination with  
POCl3 / DMA. 
58
N NH
O
Br
POCl3
DMA
N NH
O Br2
AcOH
N N
Br
Cl
46 53a  
Scheme 16. Synthesis of 5-bromo-4-chloropyrimidine 53a 
At the other hand, starting from commercially available 6-chloro-2,4-diaminopyrimidine 59 
brominating in MeOH / water in presence of NaHCO3 yields 5-bromo-6-chloro-2,4-
diaminopyrimidine 53b (Scheme 17).43 
59
N N
Cl
NH2
NH2
Br2
MeOH / H2O
1:1
N N
Cl
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53b  
Scheme 17. Synthesis of 5-bromo-6-chloro-2,4-diaminopyrimidine 53b 
The second required starting material, ortho amino mercapto substituted heterocycles 52, also 
are not commercially available. However, they can be smoothly prepared by a “Kaufmann 
reaction44 - i.e. by cleavage of an intermediately formed 2-aminothiazole ring of 62 (Scheme 
18).  
 
                                                 
42) Chesterfield, J., Mc Omie, J.F.W., Sayer, E.R., J. Chem. Soc. 1955, 3478 – 3481 
43) Okafor, C., J. Org. Chem. 1973, 38, 4386 – 4390 
44) Kaufmann, H.P., Schulz, P., Arch. Pharm. 1935, 273, 31; b) Kaufmann, H.P., Ber. 1929, 62B, 390; c) 
Kaufmann, H.P., Schubert M., German Patent 493,025, 1927, (Chem. Abstr. 1930, 24, 2754). 
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Scheme 18. Synthesis of 3-amino-6-methoxypyridine 2-(1H)-thione 52a 
This method is also applicable for the synthesis of 4-amino-5-mercapto substituted pyrimidine 
derivatives 52. Condensation of malononitrile with thiourea yields 4,6-diamino-1H-
pyrimidine-2-thione 6345. After desulfurization with Ra-Ni, the corresponding  
4,6-diaminopyrimidine 6446 is obtained in good yield. Introduction of a 5-thiocyanato 
moiety47 by using in situ generated di-cyan yields 4,6-diamino-5-thiocyanatopyrimidine 65. 
This compound can undergo a Kaufmann reaction transforming the thiocyanato function into 
a mercapto function by an intramolecular ring-closure reaction to 7-amino-2-imino-2,3-
dihydro[1,3]thiazolo[4,5-d]-pyrimidine 66, which can be hydrolyzed to obtain the desired 
mercapto derivative 52b. The reaction therefore allows the selective introduction of the 
mercapto function in position 5 of the pyrimidine ring (Scheme 19).  
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Scheme 19. Synthesis of 4,6-diamino-5-mercaptopyrimidine 52b 
                                                 
45) Bendich, A., Tinker, J.F., Brown, G.B., J. Am. Chem. Soc., 1948, 70, 3109 – 3113. 
46) Cavalieri, L.F., Bendich, A., J. Am. Chem. Soc, 1950, 72, 2587 – 2594. 
47) Okafor, C.O., J. Heterocycl. Chem., 1980, 17, 1587 – 1592. 
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Besides a Kaufmann reaction, a mercapto function can be introduced into the pyrimidine 
system by treatment of the corresponding pyrimidone with P2S5 in pyridine, in order to obtain 
4-mercapto-5-amino substituted pyrimidine derivatives 51 (Scheme 20).48 
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Scheme 20. Synthesis of 5-amino-(3H)-pyrimidine-4-thione 51 
Hereto, 5-amino-4-(3H)pyrimidone 72 needs to be synthesized. Starting from glycine ethyl 
ester hydrochloride 67, reaction with ethyl chloroformate yields ethyl [(ethoxycarbonyl)-
amino]acetate 6849 which after addition of ethylformate affords sodium (1Z)-3-ethoxy-2-
[(ethoxycarbonyl)amino]-3-oxo-1-propen-1-olate 69.50 The obtained yellow, hygroscopic salt 
is condensed with ethylthioisouronium bromide51 to give a mixture of two pyrimidine isomers 
70a+b, which are treated (without prior separation) with KOH to obtain 5-amino-2-
(ethylsulfanyl)-4(3H)-pyrimidinone 71. After removal of the 2-ethylsulfanyl moiety with Ra-
Ni, the obtained 5-amino-4-(3H)pyrimidone 72 is reacted with P2S5 to finally obtain  
5-amino- (3H)-pyrimidine-4-thione 51. 
The azophenothiazine derivatives 51 and 52 can be converted into the corresponding di-
hetaryl amines 73 andC74, respectively, by reductive removal of the sulfur atom52 partially 
                                                 
48) Duro, F., Santagati, N.A., Scapini, G., Il Farmaco, 1978, 33(12), 954-962. 
49)  Kende, A.S., Lurzio, M.J., Mendoza, J.S., J. Org. Chem., 1990, 55 (31), 918-924. 
50)  Boarland M.P.V., McOmie J.F.W., J. Chem. Soc. 1952, 4942 – 4945. 
51)  Spivak, D. Shea, K.J. J. Org. Chem. 1999, 64(13), 4627-4637. 
52) Seley, K.L., Zhang, L., Hagos, A., Quirk, S., J. Org. Chem. 2002, 67, 3365 -3373; 
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splitting the middle ring. This reaction can be seen as an inversion of the “Bernthsen” 
synthesis53 of phenothiazines (Scheme 21). 
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Scheme 21. Splitting reaction to obtain dihetarylamines 73 and 74 
2.3. Synthesis of “Split-Nucleosides”  
Di-hetaryl amines are seen as purine isosters. Glycosylation under Vorbrüggen conditions54 
allows the introduction of the sugar moiety at the bridging nitrogen atom (Scheme 22). To 
avoid extreme alkaline conditions the products were deprotected with NaOMe / MeOH. 
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Scheme 22. Synthesis of split-nucleosides C77 by Vorbrüggen condensation 
The reaction conditions were optimized using 76b (obtained from 6-chloro-N-phenyl-4-
pyrimidinamine 28a. Attempts to deprotect 76b with simultaneous conversion of the  
                                                 
53) Eicher, T., Hauptmann, S., in “Chemie der Heterocyclen, Thieme Verlag, Stuttgart, New York, 1994, 
378. 
54) a) Niedballa, U., Vorbrüggen, H., J. Org. Chem., 1974, 39, 3654; b) Vorbrüggen, H., Krolikiewicz, K., 
Bennua, B., Chem. Ber., 1981, 114, 1234; c) Vorbrüggen, H., Höfle, G., Chem. Ber., 1981, 114, 1256; d) 
Vorbrüggen, H., Bennua, B., Chem. Ber., 1981, 114, 1279. 
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6-chloro into a 6-amino-function failed. Treatment of 76b with NH3/MeOH at room 
temperature quantitatively forms the corresponding nucleoside 77b but no nucleophilic 
substitution reaction is taking place. Carring out the reaction at elevated temperature (80°C, 
1h) leads to decomposition of the nucleoside. Therefore, it is favourable to introduce first the 
desired functionalities followed by Vorbrüggen condensation. 
Since the main concept of the split-nucleosides is flexibility with retainment of the 
recognition elements of purine bases, it seems rational to introduce also a “flexible” sugar 
moiety. First attempts were carried out using diphenylamine 78 as the test-aglycon  
(Scheme 23).  
Attempts to condense 3-bromopropanol with the sodium salt of diphenylamine in dioxane 
failed, due to polymerisation of the bromoalcohol. Therefore, bromopropanol first  
was protected using TBDMS to obtain 79a. Furthermore condensation reaction with  
1-O-methylphenylsulfonyl-2,3-O-isopropylidene-glycerol 79b55 was attempted. However, so 
far, no satisfying yields of 80 were obtained; the reaction conditions have to be further 
optimized. 
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Scheme 23. Introduction of “open-sugars” to the bridging nitrogen 
2.4. Activity of Adenosine Deaminase towards 6-Chloropurine Riboside and its 
“Split “Analogues 
Adenosine deaminase (ADA, EC 3.5.4.4.) from calf intestinal mucosa catalyses the hydrolytic 
deamination of adenosine to inosine via a tetrahedral intermediate.56 Furthermore, it is known, 
                                                 
55) Zhou, D., Lagoja, I. M., Rozenski, J., Busson, R., Van Aerschot, A., Herdewijn, P., Chem. & Biochem., 
2005, 6 (12), 2298-2304. 
56) Ciuffreda, P., Buzzi, B., Alessandrini, L., Santaniello, E., Eur. J. Org. Chem., 2004, 4405-4409. 
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that ADA is able to catalyse the deamination of structurally modified purine nucleoside 
analogues57, provided that a hydroxy group is present at the 5´-position.58  
In order to gain more information on the biocatalytic capability of ADA the conversion of  
6-chloropurine riboside 81, a widely used intermediate in the synthesis of adenosine 
derivatives, into inosine 82 has been compared with an example from the split-series  
(Scheme 24). 
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Scheme 24. ADA catalyzed transformation of 77 and 81 
Split-nucleosides were designed as a new group of purine bioisosteres, therefore it was an 
interesting question, if the enzyme can recognize the pyrimidine ring of 77b as a part of a 
“flexible purine analogue” or not. The enzymatic dechlorination of compounds 81 and 77b 
was carried out in a 3% DMSO aqueous solution, conditions that do not influence the 
deaminating activity of ADA towards chloropurine nucleosides.59 The reaction has been 
monitored by HPLC. For 6-chloropurine riboside 81 the conversion to inosine 82 was 
completed after 2 hours, whereas in case of the split-analogue 77b only minor minor amounts 
were converted after 10 hours. This first investigation of the enzymatic reaction has been 
studied with the simplest split-analogue (77b) of 81, bearing a phenyl- and a chloropyrimidine 
                                                 
57) a) Ferrero, M., Gotor, V., Chem.Rev., 2000, 100, 4319-4347; b) Margolin, A.L., Borcherding, D.R., Wolf-
Kugel, D., Margolin, N., J. Org. Chem., 1994, 59, 7214-7218. 
58) Bloch, A., Robins, M.J., Mc Carthy, Jr. J.R., J. Med. Chem., 1967, 10, 908-912. 
59) Ciuffreda, P., Loseto, A., Santaniello, E., Tetrahedron, 2002, 58, 5767-5771. 
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moiety. It is plausible, that better results can be obtained using split-derivatives with a more 
pronounced structural analogy to the parent 6-chloropurine riboside 81.  
2.5. Modeling  
One of the concepts of developing split-nucleosides was to design a flexible molecule able to 
overcome problems typically associated with using crystallographic data in modelling when 
dealing with flexible enzyme binding sites. Since split-nucleosides still offer all required 
recognition elements, the overall energy of the enzyme-inhibitor complex should be lowered 
if both, enzyme and inhibitor are allowed to achieve their lowest energy conformation. This 
conformation should then be the most highly populated, increasing the chance of being the 
conformation to crystallize.60 
An enzyme fulfilling the requirement of a flexible binding site61 is SAHase (S-adenosyl-L-
homocysteine hydrolase). SAHase cleaves SAH into its two cellular components, adenosine 
(Ado) and homocysteine (Hcy), and requires the assistance of an enzyme-bound cofactor, 
NADH.62 Inhibition of SAHase by nucleoside inhibitors involves depletion of the NADH 
cofactor, which causes an intracellular accumulation of SAH, thereby elevating the 
SAH/SAM ratio. Many modified nucleosides have proven to be exceptional inhibitors of 
SAHase, and as a consequence, methyltransferases via this biofeedback mechanism, exhibit 
activity against numerous viruses including the pox viruses, arenaviruses, rhabdoviruses, 
renoviruses, vaccinia virus, parainfluenza virus, measles, ebola virus, sarcoma virus and the 
herpes viruses as well as against colon carcinoma, leukemia cells, among other cancer types.63 
Amber9 software64 was used to create the model. Atomic electrostatic charges and atom types 
for the split-nucleoside molecule to be used in the amber software package were calculated 
using Antechamber.65 The other atomic charges (enzyme and NADH) and parameters (bond, 
angle, dihedral, van der Waals, ...) used in the amber simulations are those from the parm99 
dataset.66 The model was created starting from the x-ray structure of  
                                                 
60) Seley, K.L. Quirk, S., Salim, S., Zhang, L., Hagos, A., Bioorganic & Medical Chemistry Letters, 2003, 
13, 1985-1988. 
61) a) Yin, D., Yang, X., Hu, Y., Kuczera, K., Schowen, R. L., Borchardt, R. T., Squier, T.C. Biochemistry 
2000, 39, 9811 - 9818; b) Turner, M. A., Yang, X., Yin, D., Kuczera, K., Borchardt, R.T., Howell, P.L. 
Cell Biochem. Biophys., 2000, 33, 101 - 125. 
62) Palmer, J.L., Abeles, R.H., J. Biol. Chem. 1979, 254, 1217 - 1226. 
63) a) Chiang, P.K., Pharmacol. Ther., 1998, 77, 115-134; b) De Clercq, E., Nucleosides Nucleotides, 1994, 
13, 1271-1295. 
64) Case, D.A., Cheatham, T.E., Darden, T., Gohlke, H., Luo, R. Merz, K.M. Onufriev, A. Simmerling, C. 
Wang, B. Woods, R., J. Comput. Chem. 2005, 26, 1668-1688. 
65) Wang, J.1., Wang ,W.1, Kollman, P.A.1, Case, D.A.2, J Mol Graph Model, 2006, 25, 247-260. 
66) Wang, J., Cieplak, P.,; Kollman, P.A. J., Comput. Chem., 2000, 21, 1049-1074. 
Results and Discussion 
30 
S-Adenosyl-L-Homocysteine Hydrolase (pdb code 1li4).67 The split-nucleoside was 
constructed in a C2’ endo conformation using Macromodel.68 Quatfit69 was then used to fit 
the split-nucleoside onto the Neplanocin A molecule, present in the pdb file (the base ring 
having the 2 amino groups was fit onto the base of Neoplanocin A). Neoplanocin A was then 
removed. The NADH molecule present in the x-ray structure was kept while the crystal water 
molecules were removed. 
 
Figure 5. Close-up of the inhibitor in its binding pocket. The H-bonds are shown as well as all residues making 
hydrophobic contact with the inhibitor as determined by the Ligplot software 
Molecular energy minimization was applied to the complex using Sander, while restraining 
the positions of the enzyme atoms that are at a distance of at least 5 Ångstrom from the 
inhibitor. A ligplot & hbplus analysis resulting in the H-bonds and hydrophobic contacts has 
also been performed.70  
                                                 
67) Yang, X., Hu, Y., Yin, D.H., Turner, M.A., Wang M., Borchardt., R.T., Howell P.L., Kuczera K., 
Schowen, R.L., Biochemistry, 2003; 42, 1900 – 1909. 
68) Mohamadi, F., Richards, N.G.J., Guida, W.C., Liskamp, R., Lipton, M.; Caufield, C., Chang, G., 
Hendrickson, T., Still, W.C., J. Comput. Chem., 1990, 11, 440-467. 
69) Heisterberg, D.J. Quatfit program in CCL software archives. The Ohio Supercomputer Center Columbus, 
Ohio 43212. 
70) a) McDonald, I.K., Thornton, J.M., J. Mol. Biol., 1994, 238, 777-793; b) Wallace, A.C., Laskowski, R.A., 
Thornton, J.M., Protein Engineering, 1995, 8, 127-134. 
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Figure 5 shows a close-up of the inhibitor interacting with the enzyme while Figure 6 shows 
final complex structure. They were created by bobscript, molscript and Raster3D. 71  
 
Figure 6. Overall picture of the inhibitor bound to the enzyme close to the NADH molecule. The binding site is 
coloured yellow. Secondary structure elements (alpha-helices, beta-sheets and coils are shown. 
The modeling structures indicate a nice binding between split-nucleosides and enzyme. 
However, further studies using dynamic models to calculate quantitative binding energies are 
postponed until experimental results about the SAHase activity of split-nucleosides are 
available. Since binding to an enzyme always is entropically disfavoured,72 split-nucleosides 
are designed to overcome this entropic cost by the ability to adopt more favourable 
conformations, therefore allowing more favourable binding interactions than the more rigid 
nucleoside analogues. The fact, that the split-nucleosides are found to bind in a “twisted” 
form seem to proof this hypothesis. 
                                                 
71) a) Esnouf, R.M., J. Mol. Graphics Modell., 1997, 15, 132-134; b) Kraulis, P.J., J. Appl. Cryst. 1991, 24, 
946-950; c) Merritt, E.A., Bacon, D.J. Raster3D: Methods in Enzymology 1997, 277, 505-524. 
72) Seley K.L., Salim, S., Zhang. L., O´Daniel, P.I., J. Org. Chem., 2005, 70, 1612-1619. 
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CONCLUSION  
The first part of this chapter describes the syntheses of N1-purinylnucleosides as a new class 
of pyrimidine bioisosteres. N1-Adenosine (page 7) could be isolated as the kinetic product 
during studies of the mechanism of the Vorbrüggen condensation. N1-Xanthosine (page 10) 
could be build up in a total synthesis, whereas N1-inosine (page 9) was obtained from suitably 
protected 6-chloropurine. However, the compounds turned out to be biologically inactive. 
Incorporation into oligonucleotides failed due to strong hydrogen-bridges between 5´-OH and 
6-XH (X= O, NH). To overcome these difficulties the interest now gets focused on the 
synthesis and incorporation of N3-purinylnucleosides,73 also fulfilling the criteria of 
pyrimidine-bioisosters. 
Split-nucleosides offer a new field in medicinal chemistry. This work gives a first impression 
about synthetic routes and possible applications of this novel class of substances. 
In this chapter the interest is focussed mainly on three different substance classes: split-
nucleosides and their synthetic precursours: dihetaryl amines and azaphenothiazines. 
With help of palladium catalyzed amination reaction (Hartwig-Buchwald condensation) (page 
15) dihetarylamines can be synthesized in only one step starting from an amino- and a 
halogeno compound. The reaction could be verified by several examples; however, a 
synthetic challenge lies in further optimization of the reaction conditions.74 Yields can be 
improved by choice of the base75 and use of various catalysts.76 The application of protection 
groups and modification of the solvent should allow a general application of this method. 
Investigation of the biological activities of these compounds is in progress. 
The reversal of the Bernthsen synthesis, the reductive removal of the sulphur of an 
azaphenothiazine derivative is an alternative pathway (page 26) to obtain the desired 
dihetarylamines. Since ring-closure reaction to azaphenothiazines is possible in acidic (page 
21) as well as in alkaline (page 22) circumstances high attention was paid to structure 
elucidation of the obtained reaction products. Azaphenothiazines are strongly fluorescent 
compounds showing strong structure analogy to known major groove intercalators and 
                                                 
73) Schmidt, C.L., Townsend, L.B., J. Heterocyclic Chem., 1973, 10(4), 687-8. 
74) Buchwald, S.L., Mauger, C., Mignani, G., Scholz, U., Adv. Synth. Catal., 2006, 348, 23 – 39. 
75) Lakshman, M.K., J. Organomet. Chem., 2002, 653, 234-/251. 
76) a) Prim, D., Campagne, J.-M., Joseph, D., Andrioletti, B., Tetrahedron, 2002, 58, 2041-75; b) Charles, 
M.D., Schultz, P., Buchwald, S.L., Organic Letters, 2005, 7 (18), 3965-68; c) Cristau, H.-J., Cellier, P.P., 
Spindler, J.-F., Taillefer, M., Chem. Eur. J., 2004, 10, 5607 – 5622. 
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fluorescence markers. Therefore, in future more attention will be paid to these features of 
azaphenothiazines, their use as precursors of dihetarylamines will diminish. Initial tests to 
evaluate the quantum yield, fluorescence measurements, and the evaluation of the biological 
features of this substance class are currently under investigation. 
Starting from the corresponding dihetarylamines, split-nucleosides can be obtained by 
Vorbrüggen condensation (page 26) in good yields. Currently the investigation of the 
biological properties of this novel class is in progress. Having in hand the ribo-derivatives, 
attention now is focused on the synthesis of further glycosides, using deoxy-sugars or open-
chain sugars as starting material. Since an efficient synthetic pathway to obtain ribo-split-
nucleosides is now available, the next step will be the incorporation of these compounds into 
oligonucleotides and the study of their hybridisation properties. 
 
 
The best way to have a good idea is to have a lot of ideas.  
Linus Pauling  
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SCHLUSSFOLGERUNG 
Im ersten Teil dieses Kapitels wird die Synthese von N1-Purinylnukleosiden als neue 
Pyrimidin Bioisostere beschrieben. N1-Adenosin (Seite 7) wurde als kinetisches Produkt bei 
Studien zur Vorbrüggenkondensation erhalten, wohingegen N1-Xanthosin (Seite 10) durch 
eine Totalsynthese aufgebaut und N1-Inosin (Seite 9) durch die Anwendung geeigneter 
Schutzgruppen aus 6-Cl-Purin synthetisiert wurde. Die Verbindungen erwiesen sich als 
biologisch inaktiv, der Einbau dieser Verbindungen in Oligonukleotide ist aufgrund einer 
starken Wasserstoffbrückenbindung zwischen dem 5´-OH und dem 6-XH (X= O, NH) nicht 
gelungen. N3-Purinylnukleoside73 erfüllen ebenfalls die erforderlichen Kriterien eines 
Pyrimidin Bioisosters, der Einbau dieser Verbindungen in Oligonukleotide soll die 
Untersuchung der Hybridisierungseigenschaften erlauben. 
Split-Nukleoside bieten ein neues, weitläufiges Betätigungsfeld auf dem Gebiet der 
medizinischen Chemie. Diese Arbeit gibt einen ersten Eindruck über mögliche 
Anwendungsgebiete sowie über mögliche Syntheserouten.  
In diesem Kapitel werden vor allem drei Substanzklassen beschrieben: Split-Nukleoside, 
sowie ihre synthetischen Vorstufen: Dihetarylamine und Azaphenothiazine. 
Mit Hilfe einer Palladium katalystierten Aminierungsreaktion (Hartwig-Buchwald 
Kondensation) (Seite 15) lassen sich Dihetarylamine in nur einem Reaktionssschritt 
ausgehend von einer Amino- und einer Halogenoverbindung herstellen. Die Reaktion konnte 
anhand von einigen Beispielen vorgestellt werden, eine Herausforderung liegt aber sicher 
noch in der weiteren Optimierung der Reaktionsbedingungen.74 Vor allem durch die Wahl der 
Base,76 aber auch durch den Einsatz verschiedener Katalysatoren76 kann die Ausbeute noch 
verbessert werden. Durch die Anwendung von Schutzgruppen sowie Variation der 
Lösungsmittel soll eine generelle Anwendbarkeit dieser Methode erreicht werden. 
Untersuchungen zu den biologischen Eigenschaften der Dihetarylamine sind im Gange. 
Die Umkehrung der Bernthsen Synthese – die reduktive Entfernung des Schwefels aus einem 
Azaphenothiazin Derivat (Seite 26) ist eine weitere Möglichkeit um die gewünschten 
Dihetarylamine herzustellen. Da eine Ringschluss Reaktion sowohl in saurem - (Seite 21) als 
auch in basischem Milieu (Seite 22) möglich ist wurde der Strukturaufklärung des 
entstandenen Reaktionsproduktes besondere Aufmerksamkeit geschenkt. Azaphenothiazine 
sind stark fluoreszierende Verbindungen, die eine starke Strukturanalogie zu bekannten 
Major-groove-Interkalatoren bzw. zu Fluoreszenzmarkern aufweisen. Aus diesem Grunde soll 
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in Zukunft auch mehr Andacht an die Verbindungsklasse selbst geschenkt werden. Erste 
Untersuchungen zur biologischen Aktivität, sowie Fluorenszenzmessungen und Messungen 
der Quantenausbeute wurden bereits durchgeführt.  
Split-Nukleoside lassen sich in guten Ausbeuten durch Vorbrüggen Kondensation (Seite 26) 
aus den entsprechenden Dihetarylaminen herstellen. Die Verbindungen werden auf ihre 
biologischen Eigenschaften untersucht. Die Kondensation mit weiteren Zuckerbausteinen 
(Deoxyribose, offenkettige Zucker) wird untersucht. Da nun eine effiziente 
Synthesemöglichkeit für Split-Nukleoside besteht, ist der folgende Schritt der Einbau dieser 
neuartigen Purin-Bioisostere in Oligonukleotide und die Untersuchung der 
Hybridisierungseigenschaften.  
 
The best way to have a good idea is to have a lot of ideas.  
Linus Pauling  
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3. EXPERIMENTAL PART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A theory is something nobody believes, except the person who made it. 
An experiment is something everybody believes, except the person who made it. 
Albert Einstein 
Experimental Part 
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GENERAL REMARKS: 
 
NMR spectra were recorded on a Varian, Gemini 200 spectrometer (1H 200 MHz, 13C 50 
MHz) and a Bruker AM-300 spectrometer (1H 300 MHz, 13C 75 MHz). All NH protons were 
assigned by exchange with D2O. In case of AA’BB’ systems determination of J is based on 
the assumption of an AB quartet.77 gHMQC and gHMBC NMR spectra were recorded on a 
Varian 500 MHz Unity spectrometer, operating at 499.505 MHz. Quadrature detection was 
achieved by States-Haberkorn hypercomplex mode.78 The gHMQC and gHMBC spectra in 
DMSO consisted of 1024 data points in t2 and 512 increments in t1. The data were apodized 
with a shifted sine-bell square function in both dimensions and processed toa 2K × 2K matrix.  
Mass spectrometrie was carried out at a Finnigan LC Duo spectrometer (FAB+, FAB-). Exact 
mass measurements were performed on a quadrupole - time of flight mass spectrometer  
(Q-Tof-2, Micromass, Manchester, UK) equipped with a standard electrospray ionization 
(ESI) interface. Samples were infused in a propan-2-ol : water (1 : 1) mixture at 3 µL/min.  
The reactions were monitored by thin-layer chromatography (TLC) analysis using silica gel 
plates (Kieselgel 60 F254, E. Merck). Compounds were visualized by UV irradiation and / or 
spraying with a solution of phosphomolybdic acid, followed by charring at 150°C. Preparative 
TLC was carried out with precoated TLC-Plates (0.25 mm, Merck, Silica gel 60 F254). 
Column chromatography was performed on Silica Gel 60 M (0.040-0.063 mm, E. Merck).  
HPLC purifications were performed on a HS Prep100 BDS C18 8µ (250 x 10 mm) column, 
using H2O/MeCN gradients as eluens. For UV spectroscopy UV-grade MeOH was used. 
Melting points were determined with a Kofler-block.  
Nomenclature of the obtained compounds follows the rules of IUPAC and was checked with 
Autonome.79 
 
                                                 
77) Becker, E.D., "High Resolution NMR, Theory and Chemical Application", Academic Press, New York, 
1969, 169. 
78) States, D.J., Haberkorn, R.A., Ruben, D. J., J. Magn. Res., 1982, 48, 286. 
79) ACD-Chem Sketch; http://www.acdlabs.com. 
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N
6-Isobutyryladenine (10):  
Adenine (6.70 g, 49.58 mmol) (vacuum dried) was stirred in isobutyric 
anhydride (160 mL) at 70oC (oil bath temperature) for 4 h. The TLC analysis 
showed the presence of two products, mono- and disubstituted ones. The mixture 
was cooled down to room temperature, absolute methanol (170 mL) was added, and the 
mixture was refluxed until the disubstituted product was completely decomposed (2 h). The 
solvent was evaporated, and the resulting syrup was crystallized from boiling ethanol. The 
product was crystallized from boiling ethanol to give 9.15 g of white crystals (44.6 mmol, 
90%). Rf (MeCN : CH3Cl = 1 : 1) 0.14; 
1H NMR (300 MHz, dmso-d6): δ = 1.15, 1.18 (6H, 2 
x s, 2 x CH3), 2.92 (1H, q x q, J = 6.8 Hz, CH), 8.40 (1H, s, 8-H), 8.63 (1H, s, 2-H), 11.13 
(1H, s, br, ex, NH), 12.28 (1H, s, br, ex, NHCO); 13C NMR (75 MHz, dmso-d6): δ = 19.0, 
19.3 (2 x CH3), 34.2 (CH), 113.3 (6-C), 144.4 (4-C), 146.0 (8-CH), 151.5 (2CH), 162.3 (5C), 
177.5 (C=O); FAB+ [M+H]+: 206.1.  
N
6-Isobutyryl-1-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)adenine  
An anhydrous suspension of N6-isobutyryladenine (0.90 g, 4.38 mmol) and 
1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (1.79 g, 5.63 mmol) in dry 
acetonitrile (20 mL) was washed with argon for 30 min, then N,O-
bis(trimetylsilyl)acetamide (BSA; 1.64 g, 8.09 mmol) was added. The mixture 
was stirred at 75oC for 30 min until a clear solution was obtained. Trimethylsilyl triflate 
(TMSOTf; 0.48 g, 2.11 mmol) was then added and the mixture was stirred at 75oC for 3 h. 
After cooling down to room temperature the obtained solution CH2Cl2 was diluted with 
dichloromethane (180 mL) and extracted with cold saturated solution of NaHCO3 (150 mL). 
The organic layer was dried over Na2SO4, evaporated to a yellow solid foam and then 
chromatographed on a silica gel column (12 cm x 4.5 cm) in a chloroform-acetonitrile 
gradient (from 2:1 to 1:1) to give (in order of elution):  
N
6-Isobutyryl-1,9-bis-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)adenine (12):  
Yield: 0.16 g, 0.20 mmol, 5% Rf (MeCN : CH3Cl = 1 : 1) 0.67; Exact Mass Calcd: 
C31H40N5O15 722.2521[M+H]
+; Found: 722.2524. 
N
N
H
N
N
NHi-Bu
10
N
N
Ni-Bu
N
N
AcRib
AcRib
12
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N
6-Isobutyryl-9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)adenine (9b): 
Yield: 0.21 g, 0.46 mmol, 10%), Rf (MeCN : CH3Cl = 1 : 1) 0.49; FAB
+ 
[M+H]+: 464.1. 
N
6-Isobutyryl-1-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)adenine (6b): 
Yield: 0.66 g, 1.42 mmol, 33%). Rf (MeCN : CH3Cl = 1 : 1) 0.25; 6b 
was crystallized from boiling 40% aqueous ethanol to give white 
crystals (0.59 g). mp 159-161oC; UV (MeOH): λmax 313.2 nm, λmin 
255.2 nm; 1H NMR (300 MHz, CDCl3): δ = 1.18 (6H,dd, CH(CH3)2), 
2.06, 2.18, 2.24 (9H, 3s, 3 x 3, OCOCH3), 2.65 (1H, septet, CH(CH3)2), 4.41 (1H,d, 5’b-H), 
4.51-4.55 (2H, m, 5’a-H, 4’-H), 5.34 (1H, t, 3’-H), 5.63 (1H, d, J = 4.8 Hz, 1, 2’-H), 6.65 (1H, 
s, 1’-H), 8.13 (1H, s, 8-H), 8.82 (1H, s, 2-H), 12.49 (s, 1, N7-H); 13C NMR (75 MHz, CDCl3): 
δ = 19.55, 19.84 (2 x CH(CH3)2), 20.2, 20.3, 20.7 (3 x OCOCH3), 39.5 (CH(CH3)2), 61.0 (C-
5’), 67.7 (C-3’), 74.5 (C-2’), 78.9 (C-4’), 90.3 (C-1’), 114.3 (C-5), 141.5 (C-8), 142.2 (C-2), 
148.0 (C-6), 157.0 (C-4), 168.9, 169.2, 170.2 (3 x OCOCH3), 188.9 (NCOCH), Exact Mass 
Calcd: C20H26N5O8: 464.1781[M+H]
+, Found: 464.1784. 
1-Ribofuranosyladenine (13): 
A solution of N6-isobutyryl-1-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)-
adenine (6b) (0.22 g, 0.48 mmol) in methanol saturated with ammonia 
(10 mL) was stirred at room temperature for 24 h. The reaction mixture 
was evaporated to give a white crystalline material, which was stirred in 
chloroform-methanol (1:1) at room temperature for 2 h. The precipitate was filtered off and 
the crystals were washed with chloroform-methanol (1:1). The product was crystallized from 
boiling water to give 1-ribofuranosyladenine (0.1 g, 0.45 mmol; 93%). mp decomp. >169oC; 
UV (MeOH): λmax 274.8 nm, λmin 247.6 nm, λmax 228.4 nm, Rf (MeOH : CH2Cl2 = 1 : 4) 
0.35; 1H NMR (300 MHz, dmso-d6): δ = 3.38 (3H, bs, ex, 2’-OH, 3’-OH, 5’-OH), 3.72 (2H, 
q, 5’a,b-H), 4.07 (1H, d, 4’-H), 4.12 (1H, d, 3’-H), 4.12 (1H, t, J = 5.4 Hz, 2’-H), 5.95 (1H, d, 
J = 6.0 Hz, 1’-H), 6.80 (2H, br, ex, NH2), 7.83 (1H, s, 8-H), 8.39 (1H, s, 2-H); 
1H NMR (300 
MHz, D2O): δ = 4.05 (2H, q, 5’a,b-H), 4.46 (1H, d, 4’-H), 4.49 (1H, d, 3’-H), 4.79 (1H, t, J = 
6.0 Hz, 2’-H), 6.15 (1H, d, J = 6.0 Hz, 1’-H), 8.21 (1H, s, 8-H), 8.60 (1H, s, 2-H). 13C NMR 
(75 MHz, dmso-d6): 60.5 (C-5’), 69.9 (C-3’), 72.7 (C-2’), 86.3 (C-4’), 92.2 (C-1’), 119.0 (C-
O
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5), 140.5 (C-2), 148.7 (C-6), 150.7 (C-8), 154.7 (C-4); Exact Mass C10H14N5O4 Calcd: 
268.1046 [M+H]+, Found: 268.1049. 
6-Chloro-9-(4-methoxybenzyl)-9H-purine (16): 
A mixture of 6-chloropurine (1.00g, 6.47 mmol),  
4-methoxybenzylchloride (1.11 g, 1.1 eq) and K2CO3 (1.00g) is kept in 
dry DMF (10 mL) overnight. Following dilution of the reaction mixture 
with water (400 mL) and extraction with CH2Cl2 (4 x 20 mL) the 
combined organic layers are washed with brine and dried over Na2SO4. N7 and N9 isomer 
(ratio 1 : 7) can be separated by column chromatography (CH2Cl2 : MeOH = 95 : 5). Yield: 82 
%; Rf (CH2Cl2 : MeOH = 95 : 5) 0.46; 
1H-NMR (CDCl3, 300 MHz) δ = 3.79 (3H, s, CH3), 
5.38 (2H, s, CH2), 6.85, 6.89 - 7.27, 7.29 (4H, AA´BB´), 8.09 (1H, s, 8-H), 8.77 (1H, s, 2-H); 
13C-NMR (CDCl3, 75 MHz) δ = 47.5 (CH2), 55.3 (CH3), 114.6 (3,5H Bn), 128.9 (2,6H Bn), 
128.9 (1C, Bn), 160.0 (4C, Bn), 126.5 (5-C), 145.0 (2-CH), 149.0 (6-C), 152.0 (8-CH), 152.5 
(4-C); FAB+ [M+H]+: 274.1.  
9-(4-Methoxybenzyl)-hypoxanthine (17): 
A mixture of 16 (1.00 g, 3.2 mmol) in NaOH (1N, 25 mL) is heated under 
reflux for 1 hour. After cooling to room temperature the mixture is 
carefully neutralized with AcOH (pH = 7). Oil is formed. The emulsion is 
extracted with CH2Cl2 (2 x 40 mL). After drying the organic layer over 
Na2SO4 the volatiles are removed. The obtained oil crystallized in the refrigerator. Yield: 85 
%; Rf (CH2Cl2 : MeOH = 95 : 5) 0.24; 
1H-NMR (CDCl3, 300 MHz) δ = 3.76 (3H, s, CH3), 
5.26 (2H, s, CH2), 6.82, 6.85 – 7.21, 7.24 (4H, AA´BB´) 7.65 (1H, s, 8-H), 8.35 (1H, s, 2-H), 
12.20 (1H, s, br, ex, NH); 13C-NMR (CDCl3, 75 MHz) δ = 46.5 (CH2), 55.3 (CH3), 120.0 (5-
C), 138.0 (8-CH), 146.6 (4-C), 152.5 (2-CH), 154.9 (6-C), 114.3 (3,5CH Bn), 128.6 (2,6CH 
Bn), 133.5 (1C Bn), 159.5 (4C Bn); FAB+ [M+H]+: 257.3.  
N
1-Inosine 14: 
Under nitrogen protection the base 17 (0.65 g, 2.50 mmol) is dissolved 
in dichloroethane (20 mL). BSA (0.62 g, 3.00 mmol) is added and the 
mixture is stirred at room temperature for 20 min. After cooling to 0°C 
1,2,3,5-tetra-O-acetyl-ribofuranose (0.80 g, 2.50 mmol) and TMSOTf 
(0.56 g, 2.5 mmol) is added. The mixture is allowed to come to room temperature and further 
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heated under reflux for 3 hours. After cooling to room temperature, the mixture was 
neutralized with saturated NaHCO3–solution (30 mL). The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 15 mL). The combined organic layers were 
dried over Na2SO4, the solvent was removed under reduced pressure and the residual oil was 
purified by column chromatography (silica, CH2Cl2 : MeOH = 9 : 1) to obtain 2,3,5-tri-O-
acetyl-N1-(4-methoxybenzyl)inosine 18 in 85 % yield. Rf (CH2Cl2 : MeOH = 9 : 1) 0.67; 
Exact Mass Calcd: C39H33N4O9: 701.2247 [M+H]
+, Found: 701.2247. 
A mixture of 18 (0.55g, 1.07 mmol) and (NH4)2Ce(NO3)2 in CH3CN / water (4 : 1, 20 mL) is 
kept at room temperature overnight. TLC monitoring showed complete conversion of 18 (Rf 
0.67, CH2Cl2 : MeOH = 9 : 1) to the 2,3,5-tri-O-acetyl-N
1-inosine 19 (Rf 0.47, CH2Cl2 : 
MeOH = 9 : 1). After concentration of the reaction mixture, compound 19 was further 
purified by gel-filtration (removal of the inorganic salts). The product-containing fractions 
were combined and following removal of the volatiles, compound 19 (Yield 73 %) was 
deprotected by treatment with MeOH / NH3 at room temperature. After TLC montoring 
indicated complete deprotection, the volatiles were removed under reduced pressure. The 
obtained oily product was dissolved in MeOH (2 mL) and precipitated with Et2O to give 
white crystals, which further were recrystallized from water (93 %). The obtained 
spectroscopic data are identical with those described in literature.80 
2,3,5-Tri-O-benzoyl-6-amino-N3-uridine (22): 
6-Aminouracil 21 (1.50 g, 2.50 mmol) is suspended in HMDS (10 mL), 
a catalytic amount of NH4Cl is added and the mixture is heated under 
reflux until a clear solution is obtained (1h). The excess HMDS is 
removed under reduced pressure. The obtained precipitate is dissolved 
in dichloromethane (20 mL). Tribenzoylriboseacetate (3.97 g, 2.50 mmol) and TMSOTf (0.56 
g, 2.5 mmol) are added and the mixture was kept stirring under N2-atmosphere at room 
temperature overnight. After quenching with NaHCO3–solution (30 mL) the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 15 mL). The combined 
organic layers were dried over Na2SO4, the solvent was removed under reduced pressure and 
the resulted oil was purified by column chromatography (silica, CH2Cl2 : MeOH = 9 :1). 
Yield: 91 %; Rf (CH2Cl2 : MeOH = 9 : 1) 0.68; 
1H-NMR (CDCl3, 200 MHz) δ = 4.46 (3H, m, 
                                                 
80) Montgomery, J.A., Thomas, H. J., in “Nucleic Acid Chemistry”, 553-557. 
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H4´, 2 x H5´), 4.92 (1H, s, 5-H), 5.75 (2H, s, br, ex, NH2), 6.68 (2H, m, H2´, H3´), 6.68 (1H, 
s, H1´), 7.24-7.99 (15H, m, 3 x Bz), 10.61 (1H, s, br, ex, NH); 13C-NMR (CDCl3, 50 MHz) δ 
= 63.3 (5-CH2), 70.7 (2H´), 74.3 (3H´), 75.9 (4H´), 85.2 (1CH´), 77.9 (5-CH), 151.8 (2-C), 
153.8 (5-C), 163. 5 (4-C), 127.4-133.4 (C, CH Ar Bz), 165.8, 166.5 (C=O); Exact Mass 
C30H26N3O9 Calcd: 572.1669 [M+H]
+, Found: 572.1702. 
2,3,5-Tri-O-benzoyl-5,6-diamino-N3-uridine (24): 
A mixture of 2,3,5-tri-O-benzoyl-6-amino-N3-uridine (22) (3.20 g, 5.6 
mmol) and PhN2BF4 (1.57g, 1 eq., 5.6 mmol) is dissolved in dry 
dioxane (100 mL). Immediately a bright yellow colour is observed. 
Stirring under exclusion of moisture is continued, till TLC monitoring indicates, that all 
starting material has been converted (2 h) (CH2Cl2 : MeOH = 9 : 1: 22: Rf 0.68, Diazo 
intermediate 23: 0.88, bright yellow). The reaction mixture is flushed with argon; Pd-C (0.6g, 
10 %) is added. The mixture is set under vacuum and flushed with hydrogen (ballon). The 
procedure is repeated 4 times, and then the mixture was left under H2-atmosphere vigorously 
stirring overnight. Following filtration over a bed of Celite the volatiles were removed and the 
resulting-brown oil was purified by column chromatography (500 mL silica; CH2Cl2 : MeOH 
= 95 : 5 1L, CH2Cl2 : MeOH = 9 : 1 600 mL); After removal of the solvent from the product-
containing fractions 24 is obtained as a yellow foam. Yield: 85 % both steps. %; Rf (CH2Cl2 : 
MeOH = 9 : 1) 0.57; 1H-NMR (CDCl3, 300 MHz) δ = 4.74 (3H, m, H4´, 2 x H5´), 5.75 (4H, 
s, br, ex, 2 x NH2), 6.27 (2H, m, H2´, H3´), 6.75 (1H, s, H1´), 7.29 – 8.04 (15H, m, 3 x Bz); 
13C-NMR (CDCl3, 50 MHz) δ = 62.6 (5-CH2), 67.0 (2H´), 70.3 (3H´), 74.3 (4H´), 85.7 
(1CH´), 93.9 (5-CH), 148.3 (2-C), 151.2 (5-C), 161.2 (4-C), 127.4-133.5 (C, CH Ar Bz), 
165.6, 166.0, 166.4 (C=O); Exact Mass C30H27N4O9: 587.1778 [M+H]
+; Found: 587.1782. 
N
1-Xanthosine (20): 
2,3,5-Tri-O-benzoyl-5,6-diamino-N3-uridine (24) (1.8 g, 3.1 mmol) is 
dissolved in diethoxymethylacetate (15 mL) and triethylorthoformiate 
(10 mL). A catalytic amount of TsOH is added, the mixture is heated 
under reflux for 1 hour and left at room temperature overnight. After 
concentratin the resulting oil is dissolved in CH2Cl2 and purified by column chromatography 
(silica, CH2Cl2 : MeOH = 95 : 5). After removal of the solvent from the product-containing 
fractions, 2,3,5-tri-O-benzoylxanthosine (25) was obtained as a slight tan coloured foam  
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(56 %). After verification by MS spectroscopy (Exact Mass C31H24N4O9: Calcd: 596.1543 
[M+H]+, Found: 596.1551) compound 25 was deprotected by treatment with MeOH / NH3 at 
room temperature overnight. The reaction was monitored by TLC. Following the removal of 
the volatiles, the obtained oily product was dissolved in MeOH (2 mL) and precipitated with 
Et2O to give white crystals (91%). After recrystallization from water, the obtained 
spectroscopic data are identical with those described earlier in literature.81 
1-Aminoimidazole (31):  
EthylO-tosylhydroxyimidoacetate (9.10 g, 35.3 mmol) is suspended in 60% 
HClO4 (69 mL) and vigorously stirred for 30 min. The reaction mixture is 
quenched on crushed ice (300 mL) to free the reactive intermediate O-tosylhydroxylamine 
(TSH). The mixture is extracted with CH2Cl2 (3 x 30 mL), the extracts dried over Na2SO4, 
filtered and kept below 0°C. Imidazole (2.00 g) is dissolved in a minimum of dry dioxane (5 
mL) and cooled to 0-5°C. The cooled TSH solution is added dropwise via a dropping funnel. 
Stirring at 0°C is continued for another 40 min, followed by stirring at room temperature for 
another 2 hours. After removing the volatiles the obtained crude product is purified by column 
chromatography (silica, CH2Cl2 : EtOH 2 : 1). Yield: 1.53 g (61 %) light yellow crystals; Rf 
(CH2Cl2 : EtOH 2 : 1) 0.23; 
1H-NMR (200 MHz, dmso-d6): δ = 6.85 (2H, s, br, ex, NH2), 7.14 
(1H, d, J = 7.2 Hz, 4-H), 7.47 (1H, dd, J1 = 7.2 Hz, J2 = 1.4 Hz, 5-H), 7.58 (1H, (t), J ~ 1.4 
Hz, 2-H); 13C-NMR (50 MHz, dmso-d6): δ = 122.6 (5-C), 128.3 (4-C), 135.0 (2-C); 
FAB+[M+H]+: 84.1. 
1-Allyl-4-nitroimidazole (40a):  
4(5)-Nitroimidazole (2.00 g, 17.7 mmol), allyl bromide (2.31 mL, 26.5 mmol) 
and NaH (0.64 g, 26.5 mmol) in DMF (50 mL) were stirred at room 
temperature overnight. The solvent was removed under reduced pressure and 
the residual oil was purified by column chromatography (silica, CH2Cl2). Yield: 2.50 g (92 
%); Rf (CH2Cl2 : MeOH 95 : 5) 0.77; 
1H-NMR (200 MHz, CDCl3): δ = 4.67 (2H, d, J = 5.8 
Hz, CH2=), 5.25-5.40 (2H, m, CH2N), 5.97-6.04 (1H, m, CH=), 7.46 (1H, d, J = 1.4 Hz, 2-H), 
7.79 (1H, d, J = 1.4 Hz, 5-H); 13C-NMR (50 MHz, CDCl3): δ = 50.4 (CH2N), 119.4 (CH2=), 
120.7 (5-C), 130.7 (2-C), 135.9 (CH=), 141.1 (4-C); FAB+ [M+H]+: 154.1. 
                                                 
81) Winkley, M.W. J. Chem. Soc. [Section] C: 1970, 13, 1869-74. 
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4-(3H)-Pyrimidone (46):  
A mixture of 2-thiouracil (45) (3.00 g, 23.4 mmol) and Raney nickel (4.50 g, 50% 
emulsion in water) are suspended in water (60 mL) and heated under reflux for 3h. 
After filtering hot over a bed of Celite the residue is washed with boiling MeOH (4 x 10 mL). 
The combined filtrates are concentrated to a volume of ~ 5 mL and kept in the refrigerator 
overnight. The colorless crystals formed are sucked off and dried over P2O5. Yield: 1.14 g (51 
%); Rf (CH2Cl2 : MeOH 99 :1) 0.31; 
1H-NMR (200 MHz, dmso-d6): δ = 6.33 (1H, d, J = 7.2 
Hz, 5-H), 7.91 (1H, d, J = 7.2 Hz, 6-H), 8.16 (1H, s, 2-H), 12.52 (1H, s, br, ex, NH); 13C-
NMR (50 MHz, dmso-d6): δ = 116.1 (5-CH), 150.7 (2-CH), 154.3 (6-CH), 161.4 (4-C); 
FAB+[M+H]+: 97.1. 
4,6-Dichloropyrimidine (50):  
A mixture of 4,6-dihydroxypyrimidine (49) (5.00 g, 0.045 mol) and DMA (2.0 
mL) in POCl3 (20 mL) is heated under reflux for 3 hours. The obtained dark 
brown solution is cooled to room temperature, followed by removal of the 
excess POCl3. The resulting oily residue is treated with ice-water (200 mL) and neutralized 
(NaHCO3 – attention – foaming!!); After extraction with CH2Cl2 (5 x 20 mL), the combined 
organic layers are dried over Na2SO4, and filtered through SiO2 (50 g). The column was 
washed with additional CH2Cl2 (500 mL); after removal of the volatiles the product 
crystallized in the refrigerator. Yield: 4.65 g (64 %); Rf (CH2Cl2); 0.44; 
1H-NMR (200 MHz, 
dmso-d6): δ = 8.10 (1H, s, 5-H), 8.96 (1H, s, 2-H); 13C-NMR (50 MHz, dmso-d6): δ = 122.5 
(5-CH), 159.3 (2-CH), 161.1 (4,6-C); FAB+[M+H]+: 150.0. 
Triiodoimidazole (42): 
A solution of iodine (22.50 g, 0.09 mol) in 20 % aqueous KI solution (30.00 g KI in 
150 mL) was added dropwise to a stirred solution of imidazole (3.53 g, 0.05 mol) in 
2M NaOH (24.00 g NaOH in300 mL) at room temperature. The resulting mixture is 
stirred at room temperature overnight. After neutralization with glacial acetic acid the white 
precipitate formed is filtered off, washed with water and dried over P2O5. Yield: 20.67g 
(89%); m.p. 186-190°C.82 
 
                                                 
82) Panosyan, F.B., Still, I.J.W., Can. J. Chem., 2001, 1110-1114. 
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4(5)-Iodoimidazole (43):  
Triodoimidazole (3.00 g, 6.72 mmol) and sodium sulfite (12.60 g, 99.9 mmol) were 
heated at reflux in 30% ethanol water solution (150 mL) for 24 hours. Ethanol was 
distilled off under reduced pressure. The remaining solution was filtered and the 
filtrate was extracted with diethyl ether. (4 x 30 mL). After drying the organic layer over 
Na2SO4, the volatiles were removed to obtain a colorless product. Yield: 1.29 g (quant); mp: 
136-137°C (Lit297: 137-138°C) 1H-NMR (200 MHz, dmso-d6): δ = 7.31 (1H, s, 4(5)-H), 7.65 
(1H, s, 2-H); FAB+[M+H]+: 195.0. 
1-(4-Methoxybenzyl)-4-iodoimidazole (44): 
A mixture of 4(5)-iodoimidazole (43) (1.20 g, 6.18 mmol),  
4-methoxybenzyl chloride (1.07g, 6.80 mmol) and potassium carbonate 
(1.00g) in dry DMF (10 mL) is kept at room temperature overnight. 
Following dilution with water (400 mL) the suspension is extracted with CH2Cl2 84 x 20 mL). 
The combined organic layers are washed with brine (100 mL), dried over Na2SO4 and further 
purified by column chromatography (silica, CH2Cl2 : MeOH = 95 : 5). Yield: 85 %; Rf 
(CH2Cl2 : MeOH 95 : 5); 0.64; 
1H-NMR (200 MHz, dmso-d6): δ = 3.72 (s, 3H, CH3), 4.97 
(2H, s, CH2), 6.82, 6.85 – 7.21, 7.24 (4H, AA´BB´), 6.89 (1H, s, 4CH), 7.35 (1H, s, 2CH); 
13C-NMR (50 MHz, dmso-d6): δ = 50.6 (CH2), 55.3 (CH3), 114.4, 128.5, 128.8, 159.7 
(3,5CH, 1C, 2,6-CH, 4C Bn), 81.7, 124.6, 138.7 (4-C, 5-CH, 2CH imidazole); FAB+[M+H]+: 
315.0.  
5-Bromo-4-(3H)pyrimidone (58):  
Bromine (3.3 mL, 62 mL) is added dropwise at room temperature to a solution of 
4-hydroxy(3H)pyrimidone (46) (6.00 g, 39 mmol) in AcOH (50 mL). The mixture 
was left at room temperature overnight. The formed precipitate (pyrimidine x HBr) 
is filtered off dried, and crystallized from water to afford the free base. Yield: 8.85 g, (81 %); 
Rf (CH2Cl2 : MeOH 99 : 1); 0.44; 
1H-NMR (200 MHz, dmso-d6): δ = 8.42 (1H, s, 2-H), 8.56 
(1H, s, 6-H), 12.79 (1H, s, br, ex, NH); 13C-NMR (50 MHz, dmso-d6): δ = 113.5 (5-C), 150.4 
(2-CH), 151.1 (6-CH), 157.5 (4-C); FAB+[M+H]+: 176.0. 
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5-Bromo-4-chloropyrimidine (53a):  
A mixture of 5-bromo-4-(3H)pyrimidone (58) (6.00 g, 34.2 mmol), dimethylaniline 
(DMA) (1.4 mL) and POCl3 (40.0 mL) is heated under reflux for 4 hours. The 
volatiles are distilled off, the resulted oil is treated with ice-water (200 mL), 
carefully neutralized with NaHCO3 (foaming!) and extracted with ether (5 x 30 mL). The 
combined organic layers are dried over Na2SO4. After removal of the volatiles, the residue is 
purified by a small flash column. (Yield: 4.23 g (64 %); Rf (CH2Cl2); 0.36; 
1H-NMR (200 
MHz, dmso-d6): δ = 8.80 (1H, d, J = 2.2 Hz, 2-H), 8.87 (1H, d, J = 2.2 Hz, 6-H); 13C-NMR 
(50 MHz, dmso-d6): δ = 120.5 (5-C), 156.6 (156.6 C-CH), 159.8 (2-CH), 160.2 (4-C); 
FAB+[M+H]+: 194.2. 
5-Bromo-6-chloro-2,6-diaminopyrimidine (53b):  
To a rapidly stirred solution of the pyrimidine 59 (6.00g 41.5 mmol) and 
NaHCO3 (4.00 g, 46.6 mmol) in MeOH / H2O (120 mL, 1 : 1 H2O dest.; MeOH 
HPLC grade) a solution of bromine (2 mL) in MeOH (20 mL) was added 
dropwise. After addition of half of the amount of bromine more NaHCO3 (2.00 g, 23.3 mmol) 
was added and the addition was completed. Following stirring for another hour the flocculent 
precipitate formed is filtered off and washed with cold water. Yield: 5.19 g (56 %); Rf 
(CH2Cl2 : MeOH 4 : 1); 0.43; 
13C-NMR (50 MHz, dmso-d6): δ = 97.8 (5-C), 158.3 (2-C), 
161.2 (6-C), 167.6 (4-C); ES+[M]+: 223.4. 
Kaufmann Reaction: Synthesis of the Thiocycanato- Intermediates, General Procedure:  
A mechanical stirred mixture of pyrimidine (i.e. 64) or pyridine (61), respectively (97.1 
mmol) in acetic acid (134 mL) is cooled to -10°C. After stirring for 15 min potassium 
thiocyanate dihydrate (15.72 g, 118.0 mmol) is added keeping the temperature below 0°C. 
After dropwise addition of bromine (5.40 mL, 16.9 g, 106.0 mmol) the reaction mixture turns 
from bright yellow to deep orange after 2 hours. After additional stirring at 0°C for 5 hours 
the mixture is allowed to come to room temperature overnight. Following addition of water 
(34 mL) the mixture is heated to 80°C and filtered hot. The deep orange precipitate is washed 
with hot acetic acid. Under ice-bath cooling, the combined filtrates are neutralized to pH 6.5 
with concentrated ammonia. The temperature has to be maintained below 30°C. The obtained 
yellow precipitate is filtered off and dried over P2O5.  
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4,6-Diamino-5-thiocyanatopyrimidine (65b):  
Yield: 14.21 g (88 %); Rf (CH2Cl2); 0.44; 
1H-NMR (200 MHz, dmso-d6): δ = 
7.08 (4H, s, br, ex, 2 x NH2), 7.85 (1H, s, 2-H); 
13C-NMR (50 MHz, dmso-d6): 
δ = 73.7 (5-C), 111.3 (SCN), 159.6 (2-CH), 164.4 (4,6-C); ES+[M]+: 167.7. 
2,6-Diamino-5-thiocyanato4-(3H)-pyrimidinone (65c):  
Yield: 96 %; m.p. 182-185°C (H2O); Rf (CH2Cl2 : MeOH 2 : 1) 0.80; 
1H-NMR 
(200 MHz, dmso-d6): δ = 6.73, 7.05 (2H, s, br, ex, 2 x NH2), 10.46 (1H, s, br, 
ex, NH); 13C-NMR (50 MHz, dmso-d6): δ = 66.7 (5-C), 113.0 (SCN), 156.0 (2-
C), 161.6 (6-C), 166.2 (4-C); ES+[M]+: 183.3. 
Kaufmann Reaction: Synthesis of the Mercapto- Compounds, General Procedure:  
A mixture of thiocycanato compounds 52 (30.6 mmol), KOH (24.0 g 42.8 mol) and water (61 
mL) is heated under reflux overnight. At the end of the refluxing period, charcoal (0.2 g) is 
added and heating is continued for another 15 min. After filtering hot over a bed of Celite the 
filtrate is cooled to 0°C and carefully neutralized with acetic acid (temperature has to be 
maintained below 10°C). After filtration (paper filter) the filtrate is concentrated to a volume 
of 4 mL, water (3 mL) is added and pH is adjusted to 4. The yellow precipitate formed is 
sucked off and dried over P2O5.  
4,6-Diamino-5-mercaptopyrimidine (52b):  
Yield: 4.35 g (quant.); Rf (CH2Cl2 : MeOH 5 : 1); 0.21; 
1H-NMR (200 MHz, 
dmso-d6): δ = 6.39 (4 H, s, br, ex, 2 x NH2), 7.67 (1H, s, 2-H, 11.5 (1H, br, ex, 
SH); 13C-NMR (50 MHz, dmso-d6): δ = 95.9 (5-C), 155.5 (4,6-C), 163.4 (2-CH); 
FAB+[M+H]+: 143.0. 
2,6-Diamino-5-mercapto-4-(3H)-pyrimidinone (52c):  
Yield: 97 % (CH2Cl2 : MeOH 95 : 5) 0.21; 
13C-NMR (50 MHz, dmso-d6): δ = 
80.5 (5-C), 156.5 (2-C), 164.1 (4-C), 167.6 (6-C); ES+: 158.2 [M]+. 
4,6-Diamino-1H-pyrimidine-2-thione (63):  
Sodium (9.40 g, 40.8 mmol) is dissolved in dry EtOH (300 mL). After a 
homogeneous solution is obtained, thiourea (30.00 g, 39.4 mmol) is added in a 
single portion. Stirring is continued for 10 minutes followed by addition of 
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freshly distilled malonitrile (25.00 g, 39.4 mmol). The mixture is heated under reflux for 2 
hours. After cooling to room temperature water (50 mL) is added and pH is adjusted to pH 7 
by dropwise addition of glacial acetic acid. The precipitate formed is sucked off and dried 
over P2O5. Yield: 31.20 g (70 %); Rf (CH2Cl2 : MeOH 2 : 1); 0.14; 
1H-NMR (200 MHz, 
dmso-d6): δ = 5.04 (1H, s, 5-H), 6.71 (5H, s, br, ex, NH, 2 x NH2); 13C-NMR (50 MHz, dmso-
d6): δ = 74.3 (5-CH), 159.3 (br, 4,6-C), 177.5 (2-C); FAB+[M+H]+: 143.1, [M+Na]+: 165.0. 
4,6-Diaminopyrimidine (64):  
A mixture of 4,6-diamino-1H-pyrimidine-2-thione (63) (13.00 g, 91 mmol) and 
Raney nickel (13.00 g, 50 % suspension in H2O) in water (160 mL) is heated 
under reflux for 2 hours. After filtering hot over a bed of Celite the residue is 
washed with boiling MeOH (4 x 10 mL). The combined filtrates are concentrated to a volume 
of ~ 5 mL. The compound is kept in the refrigerator overnight. The formed precipitate is 
sucked off and dried over P2O5. Yield: 9.61 g (95 %); Rf (CH2Cl2: MeOH 2 : 1); 0.10; 
1H-
NMR (200 MHz, dmso-d6): δ = 5.38 (1H, s, 5-H), 6.02 (4H, s, br, ex, 2 x NH2), 7.78 (1H, s, 
2-H); 13C-NMR (50 MHz, dmso-d6): δ = 82.9 (5-CH), 158.3 (2-CH), 163.9 (4,6-C); ES+[M]+: 
110.7. 
Ethyl[(ethoxycarbonyl)amino]acetate (68):  
A solution of glycine ethyl ester hydrochloride (35.00 g, 0.25 mol) in distilled 
water (50 mL) cooled to -5°C was carefully neutralized with a 40% aqueous 
sodium hydroxide solution (15 mL), keeping the internal temperature below 5°C. Ethyl 
chloroformate (30.00 g, 0.26 mol) was then added dropwise with vigorous stirring at a rate to 
maintain the internal temperature below 5°C. After all the ethyl chloroformate was added, the 
reaction mixture was stirred at 0°C for 30 min, at which time a second portion of a 40% 
aqueous sodium hydroxide solution (10 mL) was added. After extraction the reaction mixture 
with ether (5 x 100 mL) the organic layers were combined, dried (Na2SO4), and concentrated 
in vacuo to give a crude liquid. This liquid was then distilled to afford 32 g (87%) of 68 as a 
colorless liquid: bp 135-139 °C/15 mmHg; 1H NMR (200 MHz, dmso-d6): δ = 1.15-1.22 (6H, 
2 x t, J = 6.9 Hz, 2 x CH3), 3.84 (2H, d, J = 5.6 Hz, CH2N), 4.02-4.13 (4H, 2 x q, J = 6.9 Hz, 
2 x CH2), 7.43 (1H, t, J = 5.6 Hz, NH); 13C NMR (50 MHz, dmso-d6): δ = 13.8, 14.2 ( 2 x 
CH3), 42.4 (CH2N), 60.9, 61.0 (2 x CH2O), 156.4 (NCO2), 170.0 (CO2).  
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5-Amino-2-ethylsulfanyl-4-(3H)-pyrimidone (71):  
Ethylisothiouronium bromide (strong smell!!) is prepared according to literature.83 
Finely powdered sodium (4.87 g, 0.21 mol) is suspended in dry benzene (260 mL). 
Ethylformate (22.38 g, 0.3 mol, 24.4 mL) and ethyl[(ethoxycarbonyl)amino]acetate 
(68) (32.00 g, 0.2 mol) are added. Under exclusion of moisture the mixture is kept stirring at 
room temperature for two days, after which the metallic sodium has disappeared and the 
yellow Na-salt (69) is formed. Dry ether (CaCl2, 200 mL) is added, the salt 69 is quickly 
sucked off, stored over P2O5 and used as soon as possible without further purification.  
Ethylisothiouronium bromide (24.00 g, 0.131 mol) is dissolved in aq. KOH (9.50 g KOH, 55 
mL H2O). A solution of salt 69 (40.31 g, 0.179 mol) in water (55 mL) is added. The mixture 
is kept at room temperature for 2 days. After acidifying with AcOH a yellowish-white 
precipitate (70) is obtained and filtered off. The precipitate is dissolved in NaOH (10%, 150 
mL) and heated under reflux for 25 min. After cooling to room temperature the solution was 
acidified with AcOH, the formed precipitate was filtered off and dried over P2O5. Yield: 8.08 
g, 36 % Rf (CH2Cl2 : MeOH 5 : 1) 0.88; m.p. 158-160 °C (H2O); 
1H-NMR (200 MHz, dmso-
d6): δ = 1.21 (3H, t, J = 7.4 Hz, CH3), 2.98 (2H, q, J = 7.4 Hz, CH2), 5.47 (3H, s, br, ex, NH, 
NH2), 7.15 (1H, s, 6-H); 
13C-NMR (50 MHz, dmso-d6): δ = 15.0 (CH3), 24.3 (CH2), 128.6 (6-
CH), 131.8 (5-C), 147.9 (2-C), 161.0 (4-C); ES+[M]+: 171.6 (28 %), [M+Na]+: 193.9 (100%). 
5-Amino-4-(3H)-pyrimidone (72):  
Pyrimidine 71 (8.00 g, 0.047 mol) is suspended in water (100 mL). NH4OH (25%) 
is added, until a clear solution is obtained. Raney nickel (15.00 g, 50 % slurry in 
water) is added and the mixture is heated under reflux for 3 hours. The mixture is 
filtered hot over a bed of Celite. After removal of the volatiles, the obtained product is 
crystallized from EtOH. Yield: 84 %; Rf (CH2Cl2: MeOH = 2 : 1) 0.65; 
1H-NMR (200 MHz, 
dmso-d6): δ = 4.88 (s, br, ex NH), 7.23 (1H, s, 6-CH), 7.59 (1H, s, 2-CH); 13C-NMR (50 
MHz, dmso-d6): δ = 127.8 (2-CH), 135.9 (5-C), 139.9 (6-CH), 160.0 (4-C); ES+[M]+: 111.8 
(100%), [M+Na]+: 133.8 (37%). 
5-Amino(3H)-pyrimidin-4-thione (73):  
A mixture of pyrimidine 72 (5.00 g, 0.05 mol) and P2S5 (11.00 g, 0.05 mol) in dry 
                                                 
83) Spivak, D., Shea, K.J., J. Org. Chem., 1999, 64(13), 4627-4637. 
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pyridine (100 mL) is kept at 120°C under exlusion of moisture for 6 hours. After removal of 
the volatiles, the residue is dissolved in EtOAc and purified by gel-filtration (60 g silica, 
CH2Cl2 : MeOH = 2: 1). The black tar sticks on the column, the product containing fractions 
are combined and further extracted with water (6 x 50 mL). The water layer contains the 
product, whereas pyridine residues are found in the organic layer. After treatment of the water 
layer with charcoal and hot filtration, the volatiles are removed under reduced pressure to 
obtain yellow crystals. Yield: 56 %, Rf (CH2Cl2: MeOH = 2 : 1) 0.82; 
1H-NMR (200 MHz, 
dmso-d6): δ = 4.50 (s, br, ex NH), 7.49 (1H, s, 2-CH), 7.80 (1H, s, 6-CH); 13C-NMR (50 
MHz, dmso-d6): δ = 126.7 (6-CH), 137.5 (2-CH), 144.2 (5-C), 170.5 (4-C); FAB+[M+H]+: 
128.0. 
Hartwig-Buchwald Reaction: General Procedure  
An oven-dried flask was purged with argon, charged with (±) BINAP (46 mg, 0.0375 mmol) 
and capped with a rubber septum. The flask was purged with argon and toluene (5 mL) was 
added. The mixture was heated to 80°C with stirring until the BINAP was dissolved (~ 1 
min). The solution was cooled to room temperature, Pd(OAc)2 (11 mg, 0.05 mmol, 1 mol%) 
was added, purged with argon and toluene was used to rinse the Pd from the sides of the 
reaction vessel. The mixture was stirred at room temperature for 5 min, the solution turned 
bright orange. 4,6-dichloropyrimidine (745 mg, 5.0 mmol), arylamine (6.0 mmol) and KOtBu 
(785 mg, 7.0 mmol) were added. The mixture was purged with argon; toluene (3 mL) was 
added to rinse all compounds from the wall. The mixture was kept at 80°C till all starting 
material had been consumed (TLC; CH2Cl2 : MeOH = 10 : 1). After cooling to room 
temperature the mixture was diluted with ether (20 mL), filtered and purified by flash 
chromatography.  
6-Chloro-N-phenyl-4-aminopyrimidine (28a): 
Yield: 92 %; colorless; Rf 0.86 (CH2Cl2: MeOH = 9 : 1); 
1H-NMR (CDCl3, 
200 MHz): δ = 6.70 (1H, s, 5-H pyrim), 7.22 - 7.34 (3H, m, 2,4,6H ph), 7.43 
(2 H, (t), J = 7.6 Hz, 3,5-H ph), 7.54 (1H, s, br, ex, NH), 8.45 (1H, s, 2-H 
pyr); 13C-NMR (CDCl3, 50 MHz): δ = 102.6 (5-CH pyr), 123.2 (2,6-CH ph), 126.0 (4-CH 
ph), 129.8 (3,5-CH ph), 137.1 (1-C ph), 158.7 (2-CH pyr), 160.7 (6-C pyr), 166.2 (1-C pyr); 
FAB+[M+H]+: 206.1. 
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N4,N6-Di(3-pyridinyl)-4,6-pyrimidinediamine (29): 
Yield: 10 % Rf (CH3Cl : n-hexane 1 : 1) 0.82; 
1H-NMR (200 MHz, 
dmso-d6): δ = 6.70 (1H, s, 5-H pyrim), 7.20-7.38 (8H, m, 2 x 2,4,5,6H 
pryrid), 7.58 (1H, s, br, ex, NH), 8.46 (1H, s, 2-H pyr); Exact Mass: 
C14H13N6 Calcd.: 265.1201 [M+H]
+, Found: 265.1204. 
Dechlorination reaction: Typical Procedure:  
To a solution of halo-dihetarylamine (500 mg) in ethanol (200 mL) Raney nickel (50 % 
suspension in water; 2.5 g) was added. The mixture was heated under reflux for 1 hour. TLC 
(CH2Cl2 : MeOH = 99 :1) indicated, that all starting material had been consumed. The 
mixture was filtered hot; the precipitate was washed with ethanol. The solvent of the 
combined filtrates was removed. The obtained residue was crystallized from ether/hexane. 
N-Phenyl-4-aminopyrimidine (33a):  
Yield: 86 %; colorless; Rf 0.81 (CH2Cl2: MeOH = 9 : 1); 
1H-NMR (dmso-d6, 
300 MHz): δ = 6.73 (1H, d, 5-H pyrim), 7.20 - 7.36 (3H, m, 2,4,6H Ph), 7.48 
(2 H, (t), J = 7.6 Hz, 3,5H Ph), 7.52 (1H, d, 6-H Pyrim.), 7.54 (1 H, s, br, ex, 
NH), 8.45 (1H, s, 2-H pyr); 13C-NMR (dmso-d6, 75 MHz): δ = 107.7, 154.7, 158.0, 160.4 (5-
CH, 2-CH, 6-CH, 4-C pyrim), 120.3, 123.1, 129.2, 140.9 (2,6-CH, 4-CH, 3,5-CH, 1-C ph); 
FAB+[M+H]+: 172.1. 
Exchange of Cl to NH2: Typical Procedure: 
A pressure vessel is charged with halo-dihetarylamine (500 mg) and MeOH / NH3 (200 mL). 
After sealing, the mixture is kept at 80°C overnight. After removal of the volatiles the 
obtained product is purified by crystallization from ether. 
N
4-Phenyl-4,6-pyrimidinediamine (34): 
Yield: 78 %; colorless; Rf 0.74 (CH2Cl2: MeOH = 9 : 1); 
1H-NMR (dmso-d6, 
300 MHz): δ = 6.25 (1H, d, 5-H pyrim), 6.91 (1H, t, J = 7.08 H, 4-H, Ph), 
7.26 (2H, (t), J1 = 7.8 Hz, J2 = 7.6 Hz, 3,5-H Ph), 7.55 (2H, d, J = 7.6 Hz, 2,6-
H, Ph), 8.24 (1H, s, 2-H pyr), 9.26 (1H, s, br, ex, NH); 13C-NMR (dmso-d6, 75 MHz): δ = 
86.9, 149.6, 158.0, 160.9 (5-CH, 2-CH, 6-C, 4-C pyrim), 120.2, 122.1, 129.1, 141.0 (2,6-CH, 
4-CH, 3,5-CH, 1-C ph); FAB+[M+H]+: 187.1. 
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Exchange of Cl to OH: Typical Procedure:  
A solution of halo-dihetarylamine (0.5 g) in ethyleneglycol was treated with NaOH (0.6 g) at 
180°C for 30 minutes. Complete solution was achieved when the internal temperature reached 
110°C. After cooling to room temperature the mixture was diluted with water (25 mL), treated 
with charcoal and filtered. The clear yellow filtrate was acidified with glacial acetic acid. The 
precipitate formed was filtered off and recrystallized from EtOH / water.  
6-Anilino-4(3H)-pyrimidinone (35):  
Yield: 72 %; colorless; Rf 0.66 (CH2Cl2: MeOH = 9 : 1); 
1H-NMR (CDCl3, 
200 MHz): δ = 6.70 (1H, s, 5-H pyrim), 7.24-7.54 (6H, m, 2, 3, 4, 5,6H ph, 2-
H pyr), 7.58 (1 H, s, br, ex, NH), 9.85 (1H, s, br, ex NHCO); FAB+[M+H]+: 
188.1. 
Exchange of Cl to OMe: Typical Procedure: 
A pressure vessel is charged with halo-dihetarylamine (500 mg) and sodium methoxide (1.2 
equ.) in MeOH (200 mL). After sealing, the mixture is kept at 80°C overnight. After careful 
neutralization and removal of the volatiles, the obtained product is purified by crystallization 
from ether. 
6-Methoxy-N-phenyl-4-aminopyrimidine (36):  
Yield: 81 %; Rf (CH2Cl2 : MeOH 9 : 1) 0.72; 
1H-NMR (300 MHz, dmso-d6): 
δ = 3.32 (3H, s, CH3), 6.10 (1H, s, 5-H pyrim), 6.96 (1H, m, 4H ph), 7.28 
(2H, (m, 3,5H ph), 7.54 (2H, m, 2,6H ph), 8.34 (1H, s, 2-H pyrim), 9.12 (1H, 
s, br, ex, NH); 13C-NMR (50 MHz, dmso-d6): δ = 53.8 (CH3), 88.0, 158.2, 161.0, 163.2 (5-
CH, 2-CH, 4-C, 6-C pyrim), 120.3, 122.3, 129.1, 140.9 (2,6-CH, 4-CH, 3,5-CH, 1C ph); 
FAB+[M+H]+ 202.1. 
Ring Closure in acidic medium: Typical Procedure:  
A mixture of ortho mercapto-hetarylamine (4.0 mmol) and ortho-bromo-hetarylchloride (4.0 
mmol) is dissolved in a mixture of dioxane (5 mL) and water (10 mL). NaHSO3 (104 mg, 1 
mmol) and conc. H2SO4 (4 drops) are added and the reaction mixture is heated under reflux 
for 4 hours. Almost immediately a light yellow precipitate is formed, which turns to a fluffy 
bright yellow- orange precipitate while heating was continued. During the whole heating 
process the pH has to remain slightly acidic. After cooling to room temperature the mixture is 
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carefully neutralized to pH ~ 7; the solvents are reduced to a volume of ~ 4 mL and after 
cooling the precipitate formed is filtered off, dried over P2O5 and crystallized from acetone.  
2,4-Diamino-10H-pyrimido[5,4-b][1,4]benzothiazine (55):  
Yield: 94 %; yellow; Rf: (CH2Cl2: MeOH = 9 . 1) 0.42; green 
fluorescence at 365 nm; mp: 255-256 °C; UV UV (λmax[nm], log ε) (pH = 
1): 268 (4.78), 295 (3.82), 291 (3.81), 1H-NMR (dmso-d6, 500 MHz): δ = 
6.58 (2H, s, br, ex, 2-NH2), 6.67 (2H, s, br, ex, 4-NH2), 6.85 (1H, t, J = 7.8 Hz 7-H), 6.88 (1H, 
d, J = 7.5 Hz, 9-H), 6.96 (1H, d, J = 7.8 Hz, 6-H), 7.01 (1H, t, J = 7.6 Hz, 8-H), 9.36 (1H, s, 
br, ex, 10-H); 13C-NMR (dmso-d6, 125 MHz): δ = 73.4 (4a-C), 116.2 (9-CH), 116.7 (5aC), 
123.6 (7-CH), 126.2 (6-CH), 127.5 (8-CH), 139.3 (9a-C), 154.3 (2-C), 157.0 (4-C), 159.2 
(10a), FAB+[M+H]+: 232.1. 
10H-Dipyrimido[4,5-b:4,5-e][1,4]thiazine-2,4,9-triamine (55b):  
Yield: 92 %; orange; Rf CH2Cl2: MeOH = 9 . 1) 0.31; green fluorescence at 
365 nm; mp: > 300 °C; UV (λmax[nm], log ε): (pH = 1): 258 (2.72), 430 
(2.92); FAB+[M+H]+: 249.2. 
Ring Closure in alkaline medium: Typical Procedure:  
A mixture of ortho mercapto-hetarylamine (4.0 mmol) and ortho-bromo-hetarylchloride (4.0 
mmol) is dissolved in 1N NaOH (20 mL). Almost immediately a bright red solution is 
obtained. Stirring is continued for 4 more hours. After neutralization with glacial acetic acid a 
fluffy bright orange-red precipitate is obtained. The volatiles are concentrated to a volume of 
4 mL. After cooling the precipitate formed is filtered off, dried over P2O5 and crystallized 
from acetone / charcoal. 
2-[(3-Chloro-2-pyridinyl)sulfanyl]aniline (57a):  
Yield: 76 %; Rf (CH2Cl2 : MeOH = 9 : 1) 0.54 colorless, no fluorescence at 365 
nm; 1H-NMR (200 MHz, dmso-d6): δ = 6.73-6.83 (2H, m, 5,6 CH an), 6.92-6.98 
(1H, d xd, J = 4.8 Hz, J = 3.0 Hz, 4CH an), 7.25 (1H, (t), J = 7.6 Hz, J = 1.2 Hz, 
5-H py), 7.40 (1H, d x d, J = 7.6 Hz, J = 1.3 Hz, 3-H an), 7.55 (1H, d x d, J = 
1.2 Hz, J = 8.0 Hz, 4-H py), 8.00 (2H, s, br, ex, NH2), 8.22 (1H, d x d, J = 1.3 Hz, J = 8.0 Hz, 
6-H py); 13C-NMR (50 MHz, dmso-d6): δ = 112.1, 115.5, 118.6, 131.4, 137.7, 149.7 (2-C, 6-
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CH, 3-CH, 4-CH, 5-CH, 1-C an), 120.5, 128.9, 136.2, 147.6, 162.5 (5-CH, 3-C, 4-CH, 6-CH 
py); FAB+[M+H]+: 237.0. 
8-Chloro-10H-pyrido[2,3-b]pyrimido[4,5-e][1,4]thiazine-2,4-diamine (55d):  
Yield: 89 %; yellow; Rf: (CH2Cl2: MeOH = 9 : 1) 0.40; green 
fluorescence at 365 nm; mp: > 300 °C; UV (λmax[nm], log ε): (pH = 1): 
232 (4.10), 251 (4.15), 283 (3.79), 306 (3.96), 333 (3.67); FAB+[M+H]+: 
267.1. 
“Splitting Reaction:” Typical procedure:  
To a solution of the azaphenothiazine derivative (500 mg) in ethanol (60 mL) Raney nickel 
(50 % suspension in water; 2.5 g) was added. The mixture was heated under reflux for 4 hour. 
TLC (CH2Cl2 : MeOH = 99 :1) indicated, that all starting material had been consumed. The 
mixture was filtered hot, the precipitate was washed with ethanol. The solvent of the 
combined filtrates was removed. The obtained residue was recrystallized from ether/hexane. 
N
4-(6-Amino-4-pyrimidinyl)-2,4,6-pyrimidinetriamine (74a):  
Yield: 83 %; colorless; Rf: 0.32 (CH2Cl2: MeOH = 9 : 1); 
1H-NMR 
(dmso-d6, 200 MHz): δ = 4.49 (s, 1H, 5-H-triNH2-pyr), 6.51 (s, 4H, 2 
xNH2), 6.89 (s, br, 3H, NH2, 5-H, NH2pyr), 7.68 (s, 1H, NH), 8.02 (s, 1H, 
2-H, NH2pyr); 
13C-NMR (dmso-d6, 50 MHz): δ = 85.9 (2 x 5-CH), 156.8 
(2-CH NH2pyr), 160.7 (3 x C-NH2), 161.7 (2 x 1-C pyrim); FAB
+[M+H]+: 219.2.  
N
4-Phenyl-2,4,6-pyrimidinetriamine (73a):  
Yield: 78 %; Rf (CH2Cl2 : MeOH = 9 : 1) 0.41 ; 
1H-NMR (300 MHz, 
dmso-d6): δ = 5.25 (1H, s, 5-H pyrim), 6.23, 6.30 (4H, 2 x s, br, ex, 2 
NH2), 6.92(1H, t, J = 7.2 Hz, 4-H Ph), 7.24 (2H, (t), J
1 = 7.2 Hz, J2 = 8.0 
Hz), 7.55 (2H, d, J = 8.0 Hz), 8.85 (1H, s, br, ex, NH); 13C-NMR (50 MHz, dmso-d6): δ = 
76.1, 160.5, 161.7, 162.5 (5-CH, 2-C, 6-C, 4-C pyrim), 120.5, 121.9, 129.0, 141.2 (2,6-CH, 4-
CH, 3,5-CH, 1C ph); FAB+[M+H]+: 202.1. 
N
4-(4-pyridinyl)-2,4,6-pyrimidinetriamine (73b):  
Yield: 85 %; colorless; Rf: 0.22 (CH2Cl2: MeOH = 9 : 1); 
1H-NMR 
(dmso-d6, 200 MHz): δ = 5.96 (1H, s, 5-H pyrim), 6.52 (2H, s, br, ex, 2-
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NH2), 6.75 (1H, s, br, ex, NH), 6.93 (2H, s, br, ex, 4-NH2), 6.95 (2H, AA´BB´, J ~ 7.6 Hz, 
2,6-H py), 8.64 (2H, AA´BB´, J ~ 7.6 Hz, 3,5-H py), 13C-NMR (dmso-d6, 50 MHz): δ = 83.1 
(5-CH pyr), 109.7 (3,5CH py), 139.2 (2,6CH py), 146.0 (1C py), 158.3 (1-C pyr), 160.9 (6-C 
pyr), 166.8 (4-C pyr); FAB+[M+H]+: 203.1.  
Vorbrüggen Condensation to 76: Typical Procedure:  
Under nitrogen protection the corresponding base (4.0 mmol) is dissolved in dichloroethane 
(20 mL). BSA (0.94 g, 4.5 mmol) is added and the mixture is stirred at room temperature for 
20 min. After cooling to 0°C tribenzoylriboseacetate (1.55 g, 3.0 mmol) or tetraacetylribose 
(0.95g, 3.0 mmol), respectively, and TMSOTf (1.02 g, 4.5 mmol) is added. The mixture is 
allowed to come to room temperature and further heated under reflux for 3 hours. After 
cooling to room temperature the mixture is then neutralized with saturated NaHCO3–solution 
(30 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 15 
mL). The combined organic layers were dried over Na2SO4, the solvent was removed under 
reduced pressure and the resulting oil was purified by column chromatography (silica, CH2Cl2 
: MeOH = 99 :1). 
2,3,5-Tri-O-benzoyl-N,N-diphenylribofuranosylamine (76a):  
Yield: 34 %; Rf 0.38 (9: 1 CH2Cl2 : MeOH); 
1H-NMR (CDCl3, 200 
MHz): δ = 1.83, 2.10 (9H, 3 x CH3CO), 4.09-4.21 (3H, 2xH5´, H4´), 
4.89 (1H, m, H3´), 5.07 (1H, m, H2´), 5.87 (1H, d, J = 8.2 Hz, H1´), 
7.05-7.34 (10H, m, 2 x ph); 13C-NMR (CDCl3, 50 MHz): δ = 20.1, 20.3 
(3 x CH3), 63.5 (CH25´), 70.5 (CH3´, CH4´), 77.5 (CH2´), 89.3 (CH1´), 123.9 (2 x 4-CH ph), 
124.2 (2 x 2,6-CH ph), 129.0 (2 x 3,5-CH ph), 145.2 (2 x C-1 ph), 169.3, 169.6, 170.3 (3 x 
C=O); FAB+[M+H]+: 450.0. 
2,3,5-Tri-O-benzoyl-N-(6-chloro-4-pyrimidinyl)-N-phenylribofuranosylamine (76b):  
Yield: 45 %; Rf 0.38 (CH2Cl2 : MeOH 9: 1); 
1H-NMR (CDCl3, 200 
MHz): δ = 3.72 (1H, s, 5-CH pyr), 4.40-4.73 (3H, m, 2 x H5´, H4´), 5.40 
(1H, m, H3´), 5.53 (1H, m, H2´), 5.99 (1H, d, J = 2.7 Hz, H1´), 7.17 – 
7.98 (20H, m, 3 x Bz, ph), 8.60 (1H, s, 2-H pyr); 13C-NMR (CDCl3, 50 
MHz): δ = 63.5 (CH25´), 71.1 (CH3´, CH4´), 78.8, (CH2´), 86.1 (CH1´), 
105.1 (5-CH pyr), 128.5-133.5 (C, CH Ar), 136.4 (1-C ph), 157.9 (2-CH pyr), 160.4 (6-C 
pyr), 164.3 (1-C pyr), 165.1, 166.0 (3 x C=O); FAB+[M+H]+: 650.1. 
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2,3,5-Tri-O-acetyl-N-(4-pyrimidinyl)-N-phenylribofuranosylamine (76c):  
Yield: 47%; Rf 0.41 (CH2Cl2 : MeOH 9: 1); 
1H-NMR (300 MHz, dmso-
d6): δ = 4.29 (2H, m, 2 x H5´), 5.31 (3H, m, H2´, H3´, H4´), 6.03 (1H, d, 
J = 3.7 Hz, H2´), 7.26 (1H, t, J = 7.5 Hz, 4-CH Ph), 7.37 (2H, (t), J1 = 
7.50 Hz, J2 = 7.70 Hz), 7.48 (1H, d, J = 7.65 Hz, 5-H pyrim), 7.73 (2H, 
d, J = 7.70 Hz, 2,6-H Ph), 8.25 (1H, d, J = 7.65 Hz, 6-H pyrim), 8.77 (1H, s, 2-H pyrim); 13C-
NMR (75 MHz, dmso-d6): δ = 20.3, 20.4, 20. 7 (3 x CH3 Ac), 62.3 (CH25´), 69.4 (CH2´), 
74.8 (CH3´), 81.5 (CH4´), 93.7 (CH1´), 109.4, 140.5, 150.1, 160.5 (5-CH, 6-CH, 2-CH, 4-C 
pyrim), 122.7, 127.0, 129.1, 135.8 (2,6-CH, 4-CH, 3,5-CH, 1-C ph), 169.7, 170.0, 170.1 (3 x 
C=O Ac); FAB+[M+H]+: 430.1. 
Deprotection to 77: Typical Procedure:  
The protected nucleoside (2.0 mmol) is dissolved in NH3/ MeOH (20 mL). The mixture is 
kept at room temperature till no more starting material could be detected on TLC. After 
removal of the volatiles under reduced pressure the resulting oil was purified by flash column 
chromatography.  
N,N-diphenylribofuranosylamine (77a):  
Yield: 85 %; Rf 0.38 (CH2Cl2 : MeOH 4: 1); 
1H-NMR (dmso-d6, 200 
MHz): δ = 3.54-3.78 (3H, 2 x H5´, H4´), 4.06 (1H, m, H3´), 4.50 (1H, m, 
H2´), 4.91 (1H, t, J = 6 Hz, 5´-OH), 5.13 (1H, d, J = 6 Hz, OH), 5.25 (1H, 
d, J = 6 Hz, OH), 6.05 (1H, d, J = 8.2 Hz, H1´), 7.05-7.34 (10H, m, 2 x 
ph); 13C-NMR (CDCl3, 50 MHz): δ = 61.0 (CH25´), 69.0 (CH3´), 71.4 (CH4´), 75.8 (CH2´), 
89.4 (CH1´), 124.1 (2 x 4-CH ph), 125.0 (2 x 2,6-CH Ph), 129.4 (2 x 3,5-CH Ph), 145.0 (2 x 
C-1 ph); Exact Mass Calcd: C17H20NO4: 302.1392 [M+H]
+, Found: 302.1395. 
N-(6-chloro-4-pyrimidinyl)-N-phenylribofuranosylamine (77b):  
Yield: 91 %; Rf (CH2Cl2 : MeOH = 4 : 1) 0.42; 
1H-NMR (300 MHz, dmso-
d6): 3.60 (2H, m, 2 x H5´), 4.09 (2H, m, H3´, H4´), 4.31 (1H, m, H2´), 5.10 
(1H, t, J = 6 Hz, 5´-OH), 5.32 (1H, d, J = 6 Hz, OH), 5.56 (1H, d, J = 6 Hz, 
OH), 5.85 (1H, d, J = 6.8 Hz, H1´), 6.71 (1H, s, 5-H pyrim), 7.23-7.36 (3H, 
m, 2,4,6H ph), 7.48 (2H, (t), J = 7.6 Hz, 3,5H ph), 8.67 (1H, s, 2-H pyr); 13C-NMR (50 MHz, 
dmso-d6): δ = 61.1 (CH25´), 70.3 (CH2´), 76.2 (CH3´), 87.5 (CH4´), 96.0 (CH1´), 13C-NMR 
(CDCl3, 50 MHz): δ = 102.8 (5-CH), 123.2, 126.0, 129.8, 137.1 (2,6-CH, 4-CH, 3,5-CH, 1-C 
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ph), 156.8 (2-CH pyr), 160.3 (6-C pyr), 164.2 (1-C pyr); Exact Mass C15H17ClN3O4 Calcd: 
338.0908 [M+H]+, Found: 338.0910. 
N-(4-pyrimidinyl)-N-phenylribofuranosylamine (77c):  
Yield: 83 %; Rf (CH2Cl2 : MeOH = 4 :1) 0.40 ; 
1H-NMR (300 MHz, 
dmso-d6): δ = 3.68 (2H, m, 2 x H5´), 4.10 (2H, m, H3´, H4´), 4.21 (1H, 
m, H2´), 5.30 (1H, t, J = 6 Hz, 5´-OH), 5.42 (1H, d, J = 6 Hz, OH), 5.70 
(1H, d, J = 5.8 Hz, H1´), 5.76 (1H, d, J = 6 Hz, OH), 7.15 (1H, d, J = 7.5 
Hz, 5-H pyrim), 7.28 (1H, t, J = 7.4 Hz, 4-H ph), 7.47 (2H, (t), J1 = 7.4 Hz, J2 = 7.7 Hz, 3,5-H 
ph), 7.66 (2H, d, J = 7.7 Hz, 2,6-H ph), 8.59 (1H, d, J = 7.5 Hz, 6-H pyrim), 9.15 (1H, s, 2-H 
pyrim); 13C-NMR (50 MHz, dmso-d6): δ = 61.1 (CH25´), 70.7 (CH2´), 76.7 (CH3´), 87.9 
(CH4´), 96.3 (CH1´), 108.9, 142.2, 152.5, 152.5 (5-CH, 6-CH, 2-CH, 4-C pyrim), 122.8, 
126.5, 129.6, 136.9 (2,6-CH, 4-CH, 3,5-CH, 1-C ph); Exact Mass C15H18N3O4 Calcd: 
304.1297 [M+H]+; Found: 304.1300. 
1-O-Methylphenylsulfonyl-2,3-O-isopropylidene-glycerole (79b): 
Under ice-cooling (rac)-1,2-O-isopropylidene-1,2,3-propanetriole (2.00 g, 0.015 
mol) was added in two portions to a solution of p-toluenesulfonyl chloride (3.80 g, 
0.020 mol) in pyridine (20 mL). The mixture was stirred at 0°C for 4 hours and 
left overnight at room temperature. Methanol (3 mL) was added and the mixture was stirred 
for another 10 minutes. After evaporation of the volatiles, the residual oil was dissolved in 
CH2Cl2 (30 mL) and washed with water (2 x 20 mL). After being dried over Na2SO4, the 
organic layer was concentrated and the residue was purified by column chromatography 
(silica, CH2Cl2 ; CH2Cl2 : MeOH 99:1). Yield: 4.08 g (94%); Rf= 0.85 (CH2Cl2: MeOH = 
99:1); 1H-NMR (CDCl3): δ =1.30 (s, 3H, CH3), 1.33 (s, 3H, CH3), 2.44 (s, 3H, CH3-Ar), 3.71-
3.78 (dd, 1H, H-3’A, J(3’A,, 2’) =5.2 Hz, J(gem) =8.8 Hz), 3.98-4.06 (m, 3H, H-3’B + 2H-1’), 
4.21-4.33 (t x t, 1H, H-2’, J(3’,2’) = 5.2 Hz, J(1’,2’) = 6.0 Hz), 7.33-7.37 (d, 2H, 3,5-H-Ar, J =8.6 
Hz), 7.76-7.80 (d, 2H, 2,6-H-Ar, J =8.6 Hz); 13C-NMR (CDCl3): δ = 21.3 (CH3-Ar), 24.9, 
26.3 (2 x CH3), 65.9 (C-1’), 69.4 (C-3’), 72.7 (C-2’), 109.8 (C-4’), 127.8 (C-3,5-Ar), 129.8 
(C-2,6-Ar), 132.6 (C-4-Ar), 145.0 (C-1-Ar). Exact Mass Calcd. C13H18O5S 287.0953[M+H]
+; 
Found: 287.0952. 
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6-Chloropurine Riboside (81): 
Under nitrogen protection the 6-Cl-purine (0.46g, 2.5 mmol) is dissolved 
in dichloroethane (20 mL). BSA (0.62g, 3.0 mmol) is added and the 
mixture is stirred at room temperature for 20 min. After cooling to 0°C 
tetraacetylribose (0.79 g 2.5 mmol) and TMSOTf (0.56 g, 2.5 mmol) is 
added. The mixture is allowed to come to room temperature and further heated under reflux 
for 3 hours. After cooling to room temperature the mixture was neutralized with saturated 
NaHCO3–solution (30 mL). The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (2 x 15 mL). The combined organic layers were dried over Na2SO4, the solvent 
was removed under reduced pressure and the resulted oil was purified by column 
chromatography (silica, CH2Cl2 : MeOH = 95 : 5). Yield: 76 % protected nucleoside C81a; 
Rf (CH2Cl2 : MeOH 95 : 5) 0.80; 
1H-NMR (300 MHz, dmso-d6): δ = 2.08, 2.11, 2.15 (9H, 3 x 
s, 3 x CH3 Ac), 4.39-4.49 (3H, m, H4´2 x H5´), 5.64 (1H, (t), J = 5 Hz, H3´), 5.95 (1H, (t), J = 
5 Hz, H2´), 6.24 (1H, d, J = 5.0 Hz, H1´), 8.31 (1H, s, 2-H), 8.77 (1H, s ,8-H); 13C-NMR (75 
MHz, dmso-d6): δ = 20.3, 20.5, 20.7 (3 x CH3 Ac), 62.8 (CH5´), 70.5 (CH3´), 73.1 (CH2´), 
80.5 (CH4´, 86.9 (CH1´), 132.3 (5-C), 143.6 (8-CH), 151.2 (6-C), 151.6 (4-C), 152.3 (2-CH), 
169.3, 169.5, 170.2 (3 x C=O Ac); FAB+[M+H]+: 413.1.  
The protected nucleoside 81a (2.0 mmol) is dissolved in NH3/ MeOH (20 mL). The mixture is 
kept at room temperature till no more starting material could be detected on TLC. To remove 
traces of adenosine formed, the compound was further purified by flash chromatography 
(silica, CH2Cl2 : MeOH = 4 : 1); Yield: 81 % Rf (CH2Cl2 : MeOH = 4 = 1) 0.56; 
1H-NMR 
(300 MHz, dmso-d6): δ = 3.57- 3.72 (2H, m, 2 x H5´), 3.99 (1H, m, H4´), 4.20 (1H, m, H3´), 
4.59 (1H, m, H2´), 5.11, 5.26, 5.58 (3H, 3 x s, br, ex, 3 x OH), 6.05 (1H, d, J = 4.9 Hz, H1´), 
8.81 (1H, s, 2-H), 8.95 (1H, s ,8-H); 13C-NMR (75 MHz, dmso-d6): δ = 61.4 (CH5´), 70.5 
(CH3´), 74.4 (CH2´), 86.2 (CH4´, 88.6 (CH1´), 131.8 (5-C), 146.2 (8-CH), 149.7 (6-C), 152.1 
(4-C), 152.2 (2-CH); FAB+[M+H]+: 286.0. 
Enzymatic Deamination of Nucleosides 81 and 77b: 
Nucleosides 81 and 77b (0.02 g) in phosphate buffer (50mol, 6 mL, pH 7.4) containing  
3 % DMSO were treated with ADA (2 mg). The reaction progress was monitored by HPLC 
using phosphate buffer (pH 6.0) / acetonitrile as eluent (9:1). When the reaction was 
complete, the solution was lyophilized to afford inosine 82 (from 81). 
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ABBREVIATIONS 
Ac Acetyl 
AcOEt Ethylacetate 
AcOH Acetic acid 
AcRib 1,2,3,5-Tetra-O-acetyl-ribofuranose 
ADA Adenosine deaminase 
AICA 5-Amino-4-imidazolecarboxamide 
ATP Adenosine Triphosphate 
BINAP 2,2´-bis(dipenylphosphino)-1,1´-binaphtyl 
Bn Benzyl 
br broad (i.e. OH, or NH signals) 
BSA N,O-bis(trimethylsilyl)acetamide 
Bz Benzoyl 
BzRib 1-O-Acetyl-2,3,5-tri-O-benzoylribofuranose 
DEPT Distortionless Enhancement by Polarization Transfer 
DMA Dimethylaniline 
DMF Dimethylformamide 
DNA Desoxyribonucleic Acid 
ES = EI; Electron Impact Ionisation, detection of positive charged particels 
Et Ethyl 
Et2O Diethylether 
Et3N Triethylamine 
EtOH Ethanol 
ex exchangeable 
FAB Fast Atom Bombardment, either positive (FAB+) or negative (FAB-) charged particels 
can be detected  
FMO Frontier Molecular Orbital 
HMBC Heteronuclear Multible Bond Correlation 
HMDS Hexamethyldisilazane 
HMQC Heteronuclear Multible Quantum Coherence 
HOMO Highest Occupied Molecular Orbital 
HPLC High Pressure Liquid Chromatography 
HSQC Heteronuclear Single Quantum Coherence 
LUMO Lowest unoccupied Molecular Orbital 
m.p.  Melting point 
Me Methyl 
MeCN Acetonitile 
MeOH Methanol 
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MMTr Monomethoxytrityl 
NaOEt Sodium ethoxide 
NOE Nuclear Overhauser Effect 
3NT 3-Nitrotriazole 
Ph Phenyl 
POMCl Pivaloyloxymethyl chloride 
Py Pyridine 
Rf Retention factor 
RNA Ribonucleic Acid 
rt Room temperature 
s, d, t  singlet, dublet, triplet 
SAHase S-adenosyl-L-homocysteine hydrolase 
t-Bu tert. Butyl 
TFA Trifluoroacetic acid 
TMSOTf Trimethylsilyltrifluoromethanesulfonate 
TsOH toluene sulfonic acid 
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